Original Article
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
N Engl J Med 2009; 361:1045-1057September 10, 2009
- Abstract
Background
Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.
Methods
In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.
Results
At 12 months, the primary end point — a composite of death from vascular causes, myocardial infarction, or stroke — had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types.
Conclusions
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non–procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Media in This Article
Figure 1
Cumulative Kaplan–Meier Estimates of the Time to the First Adjudicated Occurrence of the Primary Efficacy End Point.Figure 2
Cumulative Kaplan–Meier Estimates of the Time to the First Major Bleeding End Point, According to the Study Criteria.Article Activity
- Article
In patients who have acute coronary syndromes with or without ST-segment elevation, current clinical practice guidelines1-4 recommend dual antiplatelet treatment with aspirin and clopidogrel. The efficacy of clopidogrel is hampered by the slow and variable transformation of the prodrug to the active metabolite, modest and variable platelet inhibition,5,6 an increased risk of bleeding,7,8 and an increased risk of stent thrombosis and myocardial infarction in patients with a poor response.9 As compared with clopidogrel, prasugrel, another thienopyridine prodrug, has a more consistent and pronounced inhibitory effect on platelets,5,6 resulting in a lower risk of myocardial infarction and stent thrombosis, but is associated with a higher risk of major bleeding in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention (PCI).10
Ticagrelor, a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12, provides faster, greater, and more consistent P2Y12 inhibition than clopidogrel.11,12 In a dose-guiding trial, there was no significant difference in the rate of bleeding with the use of ticagrelor at a dose of 90 mg or 180 mg twice daily and the rate with the use of clopidogrel at a dose of 75 mg daily. However, dose-related episodes of dyspnea and ventricular pauses on Holter monitoring, which occurred more frequently with ticagrelor, led to the selection of the dose of 90 mg twice daily for further studies.13 We conducted the Study of Platelet Inhibition and Patient Outcomes (PLATO) to determine whether ticagrelor is superior to clopidogrel for the prevention of vascular events and death in a broad population of patients presenting with an acute coronary syndrome.
Methods
Study Design
PLATO was a multicenter, randomized, double-blind trial. The details of the design have been published previously.14 The executive and operations committee, consisting of both academic members and representatives of the sponsor, AstraZeneca, designed and oversaw the conduct of the trial. An independent data and safety monitoring board monitored the trial and had access to the unblinded data. The sponsor coordinated the data management. Statistical analysis was performed by Worldwide Clinical Trials, a contract research organization, in collaboration with investigators at the academic centers and the sponsor, all of whom had full access to the final study data. The manuscript was drafted by the chairs of the executive and operations committee, who were academic authors and who vouch for the accuracy and completeness of the reported data. The study design was approved by the appropriate national and institutional regulatory authorities and ethics committees, and all participants provided written informed consent.
Study Patients
Patients were eligible for enrollment if they were hospitalized for an acute coronary syndrome, with or without ST-segment elevation, with an onset of symptoms during the previous 24 hours. For patients who had an acute coronary syndrome without ST-segment elevation, at least two of the following three criteria had to be met: ST-segment changes on electrocardiography, indicating ischemia; a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors (age ≥60 years; previous myocardial infarction or coronary-artery bypass grafting [CABG]; coronary artery disease with stenosis of ≥50% in at least two vessels; previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization; diabetes mellitus; peripheral arterial disease; or chronic renal dysfunction, defined as a creatinine clearance of <60 ml per minute per 1.73 m2 of body-surface area). For patients who had an acute coronary syndrome with ST-segment elevation, the following two inclusion criteria had to be met: persistent ST-segment elevation of at least 0.1 mV in at least two contiguous leads or a new left bundle-branch block, and the intention to perform primary PCI. Major exclusion criteria were any contraindication against the use of clopidogrel, fibrinolytic therapy within 24 hours before randomization, a need for oral anticoagulation therapy, an increased risk of bradycardia, and concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer.
Study Treatment
Patients were randomly assigned to receive ticagrelor or clopidogrel, administered in a double-blind, double-dummy fashion. Ticagrelor was given in a loading dose of 180 mg followed by a dose of 90 mg twice daily. Patients in the clopidogrel group who had not received an open-label loading dose and had not been taking clopidogrel for at least 5 days before randomization received a 300-mg loading dose followed by a dose of 75 mg daily. Others in the clopidogrel group continued to receive a maintenance dose of 75 mg daily. Patients undergoing PCI after randomization received, in a blind fashion, an additional dose of their study drug at the time of PCI: 300 mg of clopidogrel, at the investigator's discretion, or 90 mg of ticagrelor for patients who were undergoing PCI more than 24 hours after randomization. In patients undergoing CABG, it was recommended that the study drug be withheld — in the clopidogrel group, for 5 days, and in the ticagrelor group, for 24 to 72 hours. All patients received acetylsalicylic acid (aspirin) at a dose of 75 to 100 mg daily unless they could not tolerate the drug. For those who had not previously been receiving aspirin, 325 mg was the preferred loading dose; 325 mg was also permitted as the daily dose for 6 months after stent placement.
Outpatient visits were scheduled at 1, 3, 6, 9, and 12 months, with a safety follow-up visit 1 month after the end of treatment. The randomized treatment was scheduled to continue for 12 months, but patients left the study at their 6- or 9-month visit if the targeted number of 1780 primary end-point events had occurred by that time. Initially, patients were to be assessed by means of Holter monitoring for 7 days after randomization, until a repeat assessment at 1 month had been obtained for 2000 of the enrolled patients.
End Points
Death from vascular causes was defined as death from cardiovascular causes or cerebrovascular causes and any death without another known cause. Myocardial infarction was defined in accordance with the universal definition proposed in 2007.14,15 Evaluation for stent thrombosis was performed according to the Academic Research Consortium criteria.16 Stroke was defined as focal loss of neurologic function caused by an ischemic or hemorrhagic event, with residual symptoms lasting at least 24 hours or leading to death.
We defined major life-threatening bleeding as fatal bleeding, intracranial bleeding, intrapericardial bleeding with cardiac tamponade, hypovolemic shock or severe hypotension due to bleeding and requiring pressors or surgery, a decline in the hemoglobin level of 5.0 g per deciliter or more, or the need for transfusion of at least 4 units of red cells. We defined other major bleeding as bleeding that led to clinically significant disability (e.g., intraocular bleeding with permanent vision loss) or bleeding either associated with a drop in the hemoglobin level of at least 3.0 g per deciliter but less than 5.0 g per deciliter or requiring transfusion of 2 to 3 units of red cells. We defined minor bleeding as any bleeding requiring medical intervention but not meeting the criteria for major bleeding.
An independent central adjudication committee adjudicated all suspected primary and secondary efficacy end points as well as major and minor bleeding events.
Statistical Analysis
The primary efficacy variable was the time to the first occurrence of composite of death from vascular causes, myocardial infarction, or stroke. We estimated that 1780 such events would be required to achieve 90% power to detect a relative risk reduction of 13.5% in the rate of the primary end point in the ticagrelor group as compared with the clopidogrel group, given an event rate of 11% in the clopidogrel group at 12 months. Cox proportional-hazards models were used to analyze the data on primary and secondary end points. All patients who had been randomly assigned to a treatment group were included in the intention-to-treat analyses.
The principal secondary efficacy end point was the primary efficacy variable studied in the subgroup of patients for whom invasive management was planned at randomization. Additional secondary end points (analyzed for the entire study population) were the composite of death from any cause, myocardial infarction, or stroke; the composite of death from vascular causes, myocardial infarction, stroke, severe recurrent cardiac ischemia, recurrent cardiac ischemia, transient ischemic attack, or other arterial thrombotic events; myocardial infarction alone; death from cardiovascular causes alone; stroke alone; and death from any cause.
To address the issue of multiple testing, a hierarchical test sequence was planned. The secondary composite efficacy end points were tested individually, in the order in which they are listed above, until the first nonsignificant difference was found between the two treatment groups. Other treatment comparisons were examined in an exploratory manner. No multiplicity adjustment was made to the confidence intervals for the hazard ratios for the ticagrelor group as compared with the clopidogrel group.
The consistency of treatment effects over time was assessed by determining the relative risk ratios for the periods from randomization to 30 days and from 31 to 360 days. Another predefined objective was to compare the two treatment groups with respect to the occurrence of stent thrombosis. The primary safety end point was the first occurrence of any major bleeding event. Additional safety end points included minor bleeding, dyspnea, bradyarrhythmia, any other clinical adverse event, and results of laboratory safety tests. The consistency of effects on efficacy and safety end points was explored in 25 prespecified subgroups and 8 post hoc subgroups, without adjustment for multiple comparisons.
Results
Study Patients and Study Drugs
We recruited 18,624 patients from 862 centers in 43 countries from October 2006 through July 2008. The follow-up period ended in February 2009, when information on vital status was available for all patients except five. The two treatment groups were well balanced with regard to all baseline characteristics (Table 1Table 1
Baseline Characteristics of the Patients, According to Treatment Group.) and nonstudy medications and procedures (Table 2Table 2
Randomized Treatment, Other Treatments, and Procedures, According to Treatment Group.). Both groups started the study drug at a median of 11.3 hours (interquartile range, 4.8 to 19.8) after the start of chest pain. In the clopidogrel group, taking into account both open-label and randomized treatment, 79.1% of patients received at least 300 mg, and 19.6% at least 600 mg, of clopidogrel between the time of the index event and up to 24 hours after randomization. Premature discontinuation of the study drug was slightly more common in the ticagrelor group than in the clopidogrel group (in 23.4% of patients vs. 21.5%). The overall rate of adherence to the study drug, as assessed by the site investigators, was 82.8%, and the median duration of exposure to the study drug was 277 days (interquartile range, 179 to 365).Efficacy
The primary end point occurred significantly less often in the ticagrelor group than in the clopidogrel group (in 9.8% of patients vs. 11.7% at 12 months; hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001) (Table 3Table 3
Major Efficacy End Points at 12 Months. and Figure 1Figure 1Cumulative Kaplan–Meier Estimates of the Time to the First Adjudicated Occurrence of the Primary Efficacy End Point.). The difference in treatment effect was apparent within the first 30 days of therapy and persisted throughout the study period. As shown in Table 3 (and Figure 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org), the hierarchical testing of secondary end points showed significant reductions in the ticagrelor group, as compared with the clopidogrel group, with respect to the rates of the composite end point of death from any cause, myocardial infarction, or stroke (10.2% vs. 12.3%, P<0.001); the composite end point of death from vascular causes, myocardial infarction, stroke, severe recurrent ischemia, recurrent ischemia, transient ischemic attack, or other arterial thrombotic events (14.6% vs. 16.7%, P<0.001); myocardial infarction alone (5.8% vs. 6.9%, P=0.005); and death due to vascular causes (4.0% vs. 5.1%, P=0.001). This pattern was also reflected in a reduction in the rate of death from any cause with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). The rate of stroke did not differ significantly between the two treatment groups, although there were more hemorrhagic strokes with ticagrelor than with clopidogrel (23 [0.2%] vs. 13 [0.1%], nominal P=0.10). Concerning our first secondary objective of ascertaining the effect in patients for whom invasive treatment was planned, the rate of the primary end point was also lower with ticagrelor (8.9%, vs. 10.6% with clopidogrel; P=0.003). Among patients who received a stent during the study, the rate of definite stent thrombosis was lower in the ticagrelor group than in the clopidogrel group (1.3% vs. 1.9%, P=0.009).The results regarding the primary end point did not show significant heterogeneity in analyses of the 33 subgroups, with three exceptions (Figure 2 in the Supplementary Appendix). The benefit of ticagrelor appeared to be attenuated in patients weighing less than the median weight for their sex (P=0.04 for the interaction), those not taking lipid-lowering drugs at randomization (P=0.04 for the interaction), and those enrolled in North America (P=0.045 for the interaction).
Bleeding
The ticagrelor and clopidogrel groups did not differ significantly with regard to the rates of major bleeding as defined in the trial (11.6% and 11.2%, respectively; P=0.43) (Figure 2Figure 2
Cumulative Kaplan–Meier Estimates of the Time to the First Major Bleeding End Point, According to the Study Criteria. and Table 4Table 4
Safety of the Study Drugs.). There was also no significant difference in the rates of major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) criteria (7.9% with ticagrelor and 7.7% with clopidogrel, P=0.57) or fatal or life-threatening bleeding (5.8% in both groups, P=0.70). The absence of a significant difference in major bleeding according to the trial definition was consistent among all subgroups, without significant heterogeneity, except with regard to the body-mass index (P=0.05 for interaction) (Figure 4 in the Supplementary Appendix). The two treatment groups did not differ significantly in the rates of CABG-related major bleeding or bleeding requiring transfusion of red cells. However, in the ticagrelor group, there was a higher rate of non–CABG-related major bleeding according to the study criteria (4.5% vs. 3.8%, P=0.03) and the TIMI criteria (2.8% vs. 2.2%, P=0.03) (Figure 3 in the Supplementary Appendix). With ticagrelor as compared with clopidogrel, there were more episodes of intracranial bleeding (26 [0.3%] vs. 14 [0.2%], P=0.06), including fatal intracranial bleeding (11 [0.1%] vs. 1 [0.01%], P=0.02). However, there were fewer episodes of other types of fatal bleeding in the ticagrelor group (9 [0.1%], vs. 21 [0.3%] in the clopidogrel group; P=0.03) (Table 4).Other Adverse Events
Dyspnea was more common in the ticagrelor group than in the clopidogrel group (in 13.8% of patients vs. 7.8%) (Table 4). Few patients discontinued the study drug because of dyspnea (0.9% of patients in the ticagrelor group and 0.1% in the clopidogrel group).
Holter monitoring was performed for a median of 6 days during the first week in 2866 patients and was repeated at 30 days in 1991 patients. There was a higher incidence of ventricular pauses in the first week, but not at day 30, in the ticagrelor group than in the clopidogrel group (Table 4). Pauses were rarely associated with symptoms; the two treatment groups did not differ significantly with respect to the incidence of syncope or pacemaker implantation (Table 4).
Discontinuation of the study drug due to adverse events occurred more frequently with ticagrelor than with clopidogrel (in 7.4% of patients vs. 6.0%, P<0.001) (Table 2). The levels of creatinine and uric acid increased slightly more during the treatment period with ticagrelor than with clopidogrel (Table 4).
Discussion
PLATO shows that treatment with ticagrelor as compared with clopidogrel in patients with acute coronary syndromes significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke. A similar benefit was seen for the individual components of death from vascular causes and myocardial infarction, but not for stroke. The beneficial effects of ticagrelor were achieved without a significant increase in the rate of major bleeding.
The benefits of ticagrelor over clopidogrel were seen in patients who had an acute coronary syndrome with or without ST-segment elevation. Previous trials have shown benefits of clopidogrel in the same clinical settings.8,17-19 The advantages were seen regardless of whether patients had received appropriate initiation of treatment with the currently recommended higher loading dose of clopidogrel and regardless of whether invasive or noninvasive management was planned.20-25 The treatment effects were the same in the short term (days 0 to 30) and in the longer term (days 31 to 360). This duration of treatment benefit has also been shown with clopidogrel.26 Thus, ticagrelor appears to expand on the previously demonstrated benefits of clopidogrel across the spectrum of acute coronary syndromes.
The incremental reduction in the risk of coronary thrombotic events (i.e., myocardial infarction and stent thrombosis) through more-intense P2Y12 inhibition with ticagrelor is consistent with similar effects of prasugrel.10 As noted above, the benefits with ticagrelor were seen regardless of whether invasive or noninvasive management was planned; this issue has not been investigated with other P2Y12 inhibitors. Treatment with ticagrelor was also associated with an absolute reduction of 1.4 percentage points and a relative reduction of 22% in the rate of death from any cause at 1 year. This survival benefit from more-intense platelet inhibition with ticagrelor is consistent with reductions in the mortality rate obtained by means of platelet inhibition with aspirin in patients who had an acute coronary syndrome27,28 and with clopidogrel in patients who had myocardial infarction with ST-segment elevation.22 In contrast, other contemporary trials involving patients with an acute coronary syndrome have not shown significant reductions in the mortality rate with the use of clopidogrel,8 prasugrel,10 or glycoprotein IIb/IIIa inhibitors.29 The improved survival rate with ticagrelor might be due to the decrease in the risk of thrombotic events without a concomitant increase in the risk of major bleeding, as seen with other antithrombotic treatments in patients with an acute coronary syndrome.30-32
Since P2Y12 inhibition with ticagrelor is reversible, the antiplatelet effect dissipates more rapidly than with the thienopyridines, which are irreversible P2Y12 inhibitors. Therefore, less procedure-related bleeding might be expected. Although the rates of major bleeding were not lower with ticagrelor than with clopidogrel, the more-intense platelet inhibition with ticagrelor was not associated with an increase in the rate of any major bleeding. In contrast to the experience with prasugrel,10 which is also a more effective platelet inhibitor than clopidogrel but is irreversible, there was no increased risk of CABG-related bleeding with ticagrelor. As with prasugrel,10 non–procedure-related bleeding (spontaneous bleeding), including gastrointestinal and intracranial bleeding, was more common with ticagrelor than with clopidogrel. Although the rare episodes of intracranial bleeding were often fatal, the rates of nonintracranial fatal bleeding, death from vascular causes, and death from any other cause were lower in the ticagrelor group than in the clopidogrel group, resulting in an overall reduction in the mortality rate with ticagrelor.
Dyspnea occurred more frequently with ticagrelor than with clopidogrel.13 Most episodes lasted less than a week. Discontinuation of the study drug because of dyspnea occurred in 0.9% of patients in the ticagrelor group. Holter monitoring detected more ventricular pauses during the first week in the ticagrelor group than in the clopidogrel group,13 but such episodes were infrequent at 30 days and were rarely associated with symptoms. There were no significant differences in the rates of clinical manifestations of bradyarrhythmia between the two treatment groups.
The superiority of ticagrelor over clopidogrel with regard to the primary end point, as well as the similarity in rates of major bleeding, was consistent in 62 of 66 subgroups; the differences were significant in the remaining 4 subgroups (P<0.05 for heterogeneity). These findings may have been due to chance, given the large number of tests performed. The difference in results between patients enrolled in North America and those enrolled elsewhere raises the questions of whether geographic differences between populations of patients or practice patterns influenced the effects of the randomized treatments, although no apparent explanations have been found.
In conclusion, in patients who had an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor, as compared with clopidogrel, significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke, without an increase in the rate of overall major bleeding but with an increase in the rate of non–procedure-related bleeding.
Supported by AstraZeneca.
Dr. Wallentin reports receiving consulting fees from Regado Biosciences and Athera Biotechnologies; lecture fees from Boehringer Ingelheim, AstraZeneca, and Eli Lilly, and grant support from Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, and Schering-Plough; Dr. Becker, consulting fees from Regado Biosciences, AstraZeneca, Eli Lilly, and Bristol-Myers Squibb and grant support from Momenta Pharmaceuticals, the Medicines Company, and Bristol-Myers Squibb; Dr. Budaj, consulting fees from Sanofi-Aventis and Eli Lilly and lecture fees from Sanofi-Aventis, Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. Dr. Cannon reports having equity ownership in Automedics Medical Systems and receiving grant support from Accumetrics, AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Merck, Intekrin Therapeutics, Schering-Plough, Novartis, and Takeda. Drs. Emanuelsson and Horrow report being employees of AstraZeneca and having equity ownership in AstraZeneca; Dr. Horrow also reports receiving lecture fees from the Pharmaceutical Education and Research Institute. Dr. Husted reports receiving consulting fees from AstraZeneca, Sanofi-Aventis, and Eli Lilly and lecture fees from AstraZeneca, Sanofi-Aventis, and Bristol-Myers Squibb; Dr. Katus, consulting and lecture fees from AstraZeneca; Dr. Mahaffey, consulting fees from AstraZeneca, Bristol-Myers Squibb, Johnson and Johnson, Eli Lilly, Pfizer, and Schering-Plough, lecture fees from Bayer, Bristol-Myers Squibb, Daichii Sankyo, Eli Lilly, and Sanofi-Aventis, and grant support from AstraZeneca, Portola Pharmaceuticals, Schering-Plough, the Medicines Company, Johnson and Johnson, Eli Lilly, and Bayer; Dr. Scirica, consulting fees from AstraZeneca, Cogentus Pharmaceuticals, and Novartis, lecture fees from Eli Lilly, Daiichi Sankyo, and Sanofi-Aventis, and grant support from Astra Zeneca, Daiichi Sankyo, and Novartis. Dr. Steg reports receiving consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Endotis Pharma, GlaxoSmithKline, Medtronic, Merck Sharp and Dohme, Nycomed, Servier, the Medicines Company, Daiichi Sankyo, and Sanofi-Aventis, lecture fees from the Medicines Company, Servier, Menarini, Pierre Fabre, Boehringer Ingelheim, Bristol-Myers Squibb, Glaxo Smith Kline, Medtronic, Nycomed, and Sanofi-Aventis, and grant support from Sanofi-Aventis and having equity ownership in Aterovax. Dr. Storey reports receiving consulting fees from AstraZeneca, Eli Lilly, Daiichi Sankyo, Teva, and Schering-Plough, lecture fees from Eli Lilly, Daiichi Sankyo, and AstraZeneca, and grant support from AstraZeneca, Eli Lilly, Daiichi Sankyo, and Schering-Plough; and Dr. Harrington, consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Portola Pharmaceuticals, Schering-Plough, and AstraZeneca, lecture fees from Schering-Plough, Bristol-Myers Squibb, Sanofi-Aventis, and Eli Lilly, and grant support from Millenium Pharmaceuticals, Schering-Plough, the Medicines Company, Portola Pharmaceuticals, Astra Zeneca, and Bristol-Myers Squibb.
No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0904327) was published on August 30, 2009, at NEJM.org.
Source Information
From the Uppsala Clinical Research Center, Uppsala, Sweden (L.W., C.H., S.J.); Duke Clinical Research Institute, Durham, NC (R.C.B., K.W.M., R.A.H.); Grochowski Hospital, Warsaw, Poland (A.B.); Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Boston (C.P.C., B.M.S.); AstraZeneca Research and Development, Mölndal, Sweden (H.E.), and Wilmington, DE (J.H.); Århus University Hospital, Århus, Denmark (S.H.); Universitätsklinikum Heidelberg, Heidelberg, Germany (H.K.); Worldwide Clinical Trials U.K., Nottingham, United Kingdom (A.S.); INSERM Unité 698, Assistance Publique–Hôpitaux de Paris and Université Paris 7, Paris (P.G.S.); and the University of Sheffield, Sheffield, United Kingdom (R.F.S.).
Address reprint requests to Dr. Wallentin at Uppsala Clinical Research Center, University Hospital, 75185 Uppsala, Sweden, or at lars.wallentin@ucr.uu.se.
The Study of Platelet Inhibition and Patient Outcomes (PLATO) investigators are listed in the Appendix and the Supplementary Appendix, available with the full text of this article at NEJM.org.
Appendix
Members of select PLATO committees are as follows (with principal investigators at participating centers and members of other committees listed in the Supplementary Appendix): Executive Committee — Sweden: L. Wallentin (cochair), S. James, I. Ekman; H. Emanuelsson, A. Freij, M. Thorsen; United States: R.A. Harrington (cochair), R. Becker, C. Cannon, J. Horrow; Denmark: S. Husted; Germany: H. Katus; U.K.: A. Skene (statistician), R.F. Storey; France: P.G. Steg; Steering Committee — Italy: D. Ardissino; Australia: P. Aylward; Philippines: N. Babilonia; France: J.-P. Bassand; Poland: A. Budaj; Georgia: Z. Chapichadze; Belgium: M.J. Claeys; South Africa: P. Commerford; the Netherlands: J.H. Cornel, F. Verheugt; Slovak Republic: T. Duris; China: R. Gao; Mexico: G.C. Armando; Germany: E. Giannitsis; United States: P. Gurbel, R. Harrington, N. Kleiman, M. Sabatine, D. Weaver; Spain: M. Heras; Denmark: S. Husted; Sweden: S. James; Hungary: M. Keltai; Norway: F. Kontny; Greece: D. Kremastinos; Finland: R. Lassila; Israel: B.S. Lewis; Spain: J.L. Sendon; Hong Kong: C. Man Yu; Austria: G. Maurer; Switzerland: B. Meier; Portugal: J. Morais; Brazil: J. Nicolau; Ukraine: A. Nikolaevich Parkhomenko; Turkey: A. Oto; India: P. Pais; Argentina: E. Paolasso; Bulgaria: D. Raev; Malaysia: D.S. Robaayah Zambahari; Russia: M. Ruda; Indonesia: A. Santoso; South Korea: K.-B. Seung; Singapore: L. Soo Teik; Czech Republic: J. Spinar; Thailand: P. Sritara; United Kingdom: R. Storey; Canada: P. Théroux; Romania: M. Vintila; Taiwan: D.W. Wu; Data Monitoring Committee — United States: J.L. Anderson (chair), D. DeMets (statistician); the Netherlands: M. Simoons; United Kingdom: R. Wilcox; Belgium: F. Van de Werf.
- References
References
1
Anderson JL ,Adams CD ,Antman EM , et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-e304[Erratum, Circulation 2008;117(9):e180.]
CrossRef | Web of Science | Medline2
Antman EM ,Anbe DT ,Armstrong PW , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction -- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636[Erratum, Circulation 2005;111:2013.]
CrossRef | Medline3
Bassand JP ,Hamm CW ,Ardissino D , et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-1660
CrossRef | Web of Science | Medline4
Van de Werf F ,Bax J ,Betriu A , et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945
CrossRef | Web of Science | Medline5
Jernberg T ,Payne CD ,Winters KJ , et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173
CrossRef | Web of Science | Medline6
Wallentin L ,Varenhorst C ,James S , et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30
CrossRef | Web of Science | Medline7
Fox KA ,Mehta SR ,Peters R , et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-1208
CrossRef | Web of Science | Medline8
Yusuf S ,Zhao F ,Mehta SR ,Chrolavicius S ,Tognoni G ,Fox KK . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502[Erratum, N Engl J Med 2001;345:1506, 1716.]
Full Text | Web of Science | Medline9
Kuliczkowski W ,Witkowski A ,Polonski L , et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426-435
CrossRef | Web of Science | Medline10
Wiviott SD ,Braunwald E ,McCabe CH , et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
Full Text | Web of Science | Medline11
Storey RF ,Husted S ,Harrington RA , et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1856
CrossRef | Web of Science | Medline12
Husted S ,Emanuelsson H ,Heptinstall S ,Sandset PM ,Wickens M ,Peters G . Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047
CrossRef | Web of Science | Medline13
Cannon CP ,Husted S ,Harrington RA , et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-1851[Erratum, J Am Coll Cardiol 2007;50:2196.]
CrossRef | Web of Science | Medline14
James S ,Akerblom A ,Cannon CP , et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
CrossRef | Web of Science | Medline15
Thygesen K ,Alpert JS ,White HD , et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-2653
CrossRef | Web of Science | Medline16
Cutlip DE ,Windecker S ,Mehran R , et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351
CrossRef | Web of Science | Medline17
Mehta SR ,Yusuf S ,Peters RJ , et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533
CrossRef | Web of Science | Medline18
Sabatine MS ,Cannon CP ,Gibson CM , et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
Full Text | Web of Science | Medline19
Chen ZM ,Jiang LX ,Chen YP , et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621
CrossRef | Web of Science | Medline20
Mehta SR ,Yusuf S ,Peters RJ , et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533
CrossRef | Web of Science | Medline21
Sabatine MS ,Cannon CP ,Gibson CM , et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-1232
CrossRef | Web of Science | Medline22
Bonello L ,Camoin-Jau L ,Armero S , et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10
CrossRef | Web of Science | Medline23
Collet JP ,Silvain J ,Landivier A , et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 2008;118:1225-1233
CrossRef | Web of Science | Medline24
Lotrionte M ,Biondi-Zoccai GG ,Agostoni P , et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007;100:1199-1206
CrossRef | Web of Science | Medline25
Montalescot G ,Sideris G ,Meuleman C , et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938
CrossRef | Web of Science | Medline26
Yusuf S ,Mehta SR ,Zhao F , et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972
CrossRef | Web of Science | Medline27
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
Web of Science | Medline28
Antithrombotic Trialists' Collaboration
CrossRef | Web of Science29
Boersma E ,Harrington RA ,Moliterno DJ , et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198[Erratum, Lancet 2002;359:2120.]
CrossRef | Web of Science | Medline30
Yusuf S ,Mehta SR ,Chrolavicius S , et al. Effects of fondaparinux, on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-1530
CrossRef | Web of Science | Medline31
Yusuf S ,Mehta SR ,Chrolavicius S , et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476
Full Text | Web of Science | Medline32
Stone GW ,Witzenbichler B ,Guagliumi G , et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230
Full Text | Web of Science | Medline
- Citing Articles (448)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
Luke Kim, Konstantinos Charitakis, Rajesh V. Swaminathan, Dmitriy N. Feldman. (2012) Novel Antiplatelet Therapies. Current Atherosclerosis Reports 14:1, 78-84
CrossRef3
William M. Weightman, Neville M. Gibbs. (2012) Management of coagulation. Current Opinion in Anaesthesiology 25:1, 86-95
CrossRef4
Mark R. Thomas, Robert F. Storey. (2012) Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine 14:1, 24-38
CrossRef5
Ulrica Alström, Fredrik Granath, Örjan Friberg, Anders Ekbom, Elisabeth Ståhle. (2012) Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. Scandinavian Cardiovascular Journal 46:1, 39-44
CrossRef6
K Butler, R Teng. (2012) Evaluation and Characterization of the Effects of Ticagrelor on Serum and Urinary Uric Acid in Healthy Volunteers. Clinical Pharmacology & Therapeutics 91:2, 264-271
CrossRef7
Davide Capodanno, Valeria Calvi, Corrado Tamburino. (2012) Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of Cardiovascular Medicine 13:2, 162-163
CrossRef8
Julio F. Marchini, Andre Manica, Kevin Croce. (2012) Stent Thrombosis: Understanding and Managing a Critical Problem. Current Treatment Options in Cardiovascular Medicine 14:1, 91-107
CrossRef9
Sergio Leonardi, Pierluigi Tricoci, Kenneth W. Mahaffey. (2012) Promises of PAR-1 Inhibition in Acute Coronary Syndrome. Current Cardiology Reports 14:1, 32-39
CrossRef10
Haiyan Li, Kathleen Butler, Li Yang, Zhenghua Yang, Renli Teng. (2012) Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects. Clinical Drug Investigation 32:2, 87-97
CrossRef11
Robert W. Harrison, Kenneth W. Mahaffey. (2012) Clopidogrel and PPI Interaction: Clinically Relevant or Not?. Current Cardiology Reports 14:1, 49-58
CrossRef12
Thomas Höchtl, Iannis Tentzeris, Karsten Schrör, Kurt Huber. (2012) Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundamental & Clinical Pharmacology 26:1, 2-10
CrossRef13
Mathieu Pankert, Jacques Quilici, Thomas Cuisset. (2012) Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research 5:1, 41-51
CrossRef14
Alexander Altenburg, Patrick Haage. (2012) Antiplatelet and Anticoagulant Drugs in Interventional Radiology. CardioVascular and Interventional Radiology 35:1, 30-42
CrossRef15
Erin Y Oh, Teena Abraham, Nasser Saad, Jonathan H Rapp, Fabienne L Vastey, Eric Balmir. (2012) A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opinion on Pharmacotherapy 13:2, 175-191
CrossRef16
Jean-Philippe Collet, Stephen O’Connor. (2012) Clinical effects and outcomes with new P2Y12 inhibitors in ACS. Fundamental & Clinical Pharmacology 26:1, 16-18
CrossRef17
Harvey D. White, Derek P. Chew, Harold L. Dauerman, Kenneth W. Mahaffey, C. Michael Gibson, Gregg W. Stone, Luis Gruberg, Robert A. Harrington, Deepak L. Bhatt. (2012) Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. American Heart Journal 163:2, 182-190.e4
CrossRef18
Sisira Siribaddana. (2012) Cardiac dysfunction in the CABG patient. Current Opinion in Pharmacology
CrossRef19
Charles Knight, Adam D. Timmis. (2012) Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia (English Edition) 31:2, 179-188
CrossRef20
Giovanni Davì, Natale Vazzana, Simona Sestili. (2012) Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins & Other Lipid Mediators
CrossRef21
Udaya S. Tantry, Eliano P. Navarese, Paul A. Gurbel. (2012) Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interventional Cardiology Clinics
CrossRef22
P. W. Armstrong, R. A. Harrington. (2012) Road mapping ATLAS ACS 2: are we there yet?. European Heart Journal
CrossRef23
Joanne Shannon, Antonio Colombo. (2012) Revascularization in multivessel CAD: a functional approach. Nature Reviews Cardiology
CrossRef24
P. A. Gurbel, E. M. Ohman, Y.-H. Jeong, U. S. Tantry. (2012) Toward a therapeutic window for antiplatelet therapy in the elderly. European Heart Journal
CrossRef25
Monte Malach, William J. Baumol. (2012) Opportunities for Cost Reduction of Medical Care: Part 3. Journal of Community Health
CrossRef26
Dobri Hazarbasanov, Vasil Velchev, Bozhidar Finkov, Arman Postadjian, Emil Kostov, Nizar Rifai, Dániel Aradi. (2012) Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis
CrossRef27
Robert Janknegt, Lex Ruiters, Hugo ten Cate. (2012) InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy1-29
CrossRef28
Tricoci, Pierluigi, Huang, Zhen, Held, Claes, Moliterno, David J., Armstrong, Paul W., Van de Werf, Frans, White, Harvey D., Aylward, Philip E., Wallentin, Lars, Chen, Edmond, Lokhnygina, Yuliya, Pei, Jinglan, Leonardi, Sergio, Rorick, Tyrus L., Kilian, Ann M., Jennings, Lisa H.K., Ambrosio, Giuseppe, Bode, Christoph, Cequier, Angel, Cornel, Jan H., Diaz, Rafael, Erkan, Aycan, Huber, Kurt, Hudson, Michael P., Jiang, Lixin, Jukema, J. Wouter, Lewis, Basil S., Lincoff, A. Michael, Montalescot, Gilles, Nicolau, José Carlos, Ogawa, Hisao, Pfisterer, Matthias, Prieto, Juan Carlos, Ruzyllo, Witold, Sinnaeve, Peter R., Storey, Robert F., Valgimigli, Marco, Whellan, David J., Widimsky, Petr, Strony, John, Harrington, Robert A., Mahaffey, Kenneth W., . (2012) Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine 366:1, 20-33
Full Text29
Roe, Matthew T., Ohman, E. Magnus, . (2012) A New Era in Secondary Prevention after Acute Coronary Syndrome. New England Journal of Medicine 366:1, 85-87
Full Text30
J. J. W. Verschuren, S. Trompet, J. A. M. Wessels, H.-J. Guchelaar, M. P. M. de Maat, M. L. Simoons, J. W. Jukema. (2012) A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. European Heart Journal 33:2, 165-175
CrossRef31
Dennis J. Cada, Terri L. Levien, Danial E. Baker. (2012) Formulary Drug Reviews - Ticagrelor. Hospital Pharmacy 47:1, 47-56
CrossRef32
Guliz Erdem, Marcus Flather. (2012) Assessing Bleeding Risk in Acute Coronary Syndromes. Revista Española de Cardiología (English Edition) 65:1, 4-6
CrossRef33
Guliz Erdem, Marcus Flather. (2012) Evaluación del riesgo de hemorragia en los síndromes coronarios agudos. Revista Española de Cardiología 65:1, 4-6
CrossRef34
Sukhjinder S. Nijjer, Justin E. Davies, Darrel P. Francis. (2012) Quantitative comparison of clopidogrel 600mg, prasugrel and ticagrelor, against clopidogrel 300mg on major adverse cardiovascular events and bleeding in coronary stenting: Synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. International Journal of Cardiology
CrossRef35
Jeffrey D. Wessler, Fidencio Saldana, Robert P. Giugliano. (2012) Bridging therapy after recent stent implantation: case report and review of data. Cardiovascular Revascularization Medicine 13:1, 30-38
CrossRef36
Eric L. Eisenstein, David F. Kong, Patricia A. Cowper, Jay P. Bae, Krishnan Ramaswamy, Kevin J. Anstrom. (2012) Nonfatal myocardial infarction and long-term outcomes in coronary artery disease. American Heart Journal 163:1, 95-103
CrossRef37
Tullio Palmerini, Laura Alessi, Nicole Rizzo, George Dangas. (2012) Percutaneous revascularization of left main. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef38
Alberto Menozzi, Daniela Lina, Giulio Conte, Francesco Mantovani, Diego Ardissino. (2012) Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy 13:1, 27-42
CrossRef39
Nanette K. Wenger. (2012) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): Highlights for the Clinician. Clinical Cardiology 35:1, 3-8
CrossRef40
Omar Ait-Mokhtar, Laurent Bonello, Saida Benamara, Franck Paganelli. (2012) High on Treatment Platelet Reactivity. Heart, Lung and Circulation 21:1, 12-21
CrossRef41
Kyung Woo Park, Hyo-Soo Kim. (2012) Options to Overcome Clopidogrel Response Variability. Circulation Journal 76:2, 287-292
CrossRef42
Grzegorz Grzesk, Marek Kozinski, Eliano Pio Navarese, Marek Krzyzanowski, Elzbieta Grzesk, Aldona Kubica, Jolanta Maria Siller-Matula, Fausto Castriota, Jacek Kubica. (2012) Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thrombosis Research
CrossRef43
Thomas O. Bergmeijer, Jurriën M. ten Berg. (2012) Valor de la determinación del genotipo de CYP2C19 *2 y *17 en la práctica clínica. Prometedor, aunque todavía no está listo. Revista Española de Cardiología
CrossRef44
Thomas O. Bergmeijer, Jurriën M. ten Berg. (2012) Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. Revista Española de Cardiología (English Edition)
CrossRef45
J. A. Jakubowski, N. Bourguet, D. Boulay-Moine, A. Sugidachi, S. Yamaguchi, P. Barragan, C. Zhou, M. Moulard. (2012) Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y12 inhibition. Thrombosis and Haemostasis 107:2,
CrossRef46
S. D. Kristensen, M. Würtz, E. L. Grove, R. De Caterina, K. Huber, D. J. Moliterno, F.-J. Neumann. (2012) Contemporary use of glycoprotein IIb/IIIa inhibitors. Thrombosis and Haemostasis 107:2,
CrossRef47
Jenny Öhman, Ramesh Kudira, Sebastian Albinsson, Björn Olde, David Erlinge. (2012) Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochemical and Biophysical Research Communications
CrossRef48
Peter Damman, Pier Woudstra, Wichert J. Kuijt, Robbert J. Winter, Stefan K. James. (2011) P2Y12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis
CrossRef49
, B. Scheller, B. Levenson, M. Joner, R. Zahn, V. Klauss, C. Naber, V. Schächinger, A. Elsässer. (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. Der Kardiologe 5:6, 411-435
CrossRef50
Thomas Cuisset, Mathieu Pankert, Jacques Quilici. (2011) Synergy between pharmacological and mechanical reperfusion in ST-segment elevation myocardial infarction patients. Journal of Cardiovascular Medicine 12:12, 860-867
CrossRef51
G. DE LUCA, F. BELLANDI, K. HUBER, M. NOC, A. S. PETRONIO, H. -R. ARNTZ, M. MAIOLI, H. M. GABRIEL, S. ZORMAN, M. DE CARLO, T. RAKOWSKI, M. GYONGYOSI, D. DUDEK. (2011) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. Journal of Thrombosis and Haemostasis 9:12, 2361-2370
CrossRef52
AMEET BAKHAI, JEAN FERRIERES, ANDRES IÑIGUEZ, MAGALI SARTRAL, MARK BELGER, CLAUDE SCHMITT, UWE ZEYMER. (2011) Clinical Outcomes, Resource Use, and Costs at 1 Year in Patients with Acute Coronary Syndrome Undergoing PCI:. Journal of Interventional Cardiologyno-no
CrossRef53
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef54
R. F. Storey, R. C. Becker, R. A. Harrington, S. Husted, S. K. James, F. Cools, P. G. Steg, N. S. Khurmi, H. Emanuelsson, A. Cooper, R. Cairns, C. P. Cannon, L. Wallentin. (2011) Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal 32:23, 2945-2953
CrossRef55
Giuseppe Musumeci, Emilio Di Lorenzo, Marco Valgimigli. (2011) Dual antiplatelet therapy duration. Current Opinion in Cardiology 26, S4-S14
CrossRef56
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef57
Marieke L. Fokkema, Wouter G. Wieringa, Iwan C. van der Horst, Eric Boersma, Felix Zijlstra, Bart J. de Smet. (2011) Quantitative Analysis of the Impact of Total Ischemic Time on Myocardial Perfusion and Clinical Outcome in Patients With ST-Elevation Myocardial Infarction. The American Journal of Cardiology 108:11, 1536-1541
CrossRef58
C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.-P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, S. D. Kristensen, J. Morais, F.-J. Neumann, L. H. Rasmussen, A. Siegbahn, P.-G. Steg, R. F. Storey, F. Van de Werf, F. Verheugt. (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal 32:23, 2922-2932
CrossRef59
Thomas Gremmel, Christoph W. Kopp, Deddo Moertl, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christine Mannhalter, Sabine Steiner. (2011) Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thrombosis Research
CrossRef60
Paul St. Laurent. (2011) Acute Coronary Syndrome: New and Evolving Therapies. Critical Care Nursing Clinics of North America 23:4, 559-571
CrossRef61
Robert F. Storey, Richard C. Becker, Robert A. Harrington, Steen Husted, Stefan K. James, Frank Cools, Philippe Gabriel Steg, Nardev S. Khurmi, Hakan Emanuelsson, Soo Teik Lim, Christopher P. Cannon, Hugo A. Katus, Lars Wallentin. (2011) Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy). The American Journal of Cardiology 108:11, 1542-1546
CrossRef62
R. C. Becker, J. P. Bassand, A. Budaj, D. M. Wojdyla, S. K. James, J. H. Cornel, J. French, C. Held, J. Horrow, S. Husted, J. Lopez-Sendon, R. Lassila, K. W. Mahaffey, R. F. Storey, R. A. Harrington, L. Wallentin. (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal 32:23, 2933-2944
CrossRef63
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 32:23, 2999-3054
CrossRef64
G. Lemesle, C. Delhaye. (2011) La thrombose de stent, de plus en plus rare !. Annales de Cardiologie et d'Angéiologie 60:6, 338-346
CrossRef65
Chee Tang Chin, William S. Weintraub, David Dai, Rajendra H. Mehta, John S. Rumsfeld, H. Vernon Anderson, John C. Messenger, Michael A. Kutcher, Eric D. Peterson, Ralph G. Brindis, Sunil V. Rao. (2011) Trends and predictors of length of stay after primary percutaneous coronary intervention: A report from the CathPCI Registry. American Heart Journal 162:6, 1052-1061
CrossRef66
Ninian N. Lang, Ingibjörg J. Guðmundsdóttir, David E. Newby. (2011) Vascular PAR-1: Activity and Antagonism. Cardiovascular Therapeutics 29:6, 349-361
CrossRef67
J. A. de Lemos, E. S. Brilakis. (2011) No free lunches: balancing bleeding and efficacy with ticagrelor. European Heart Journal 32:23, 2919-2921
CrossRef68
Kenneth Todd Moore, Alexei Nikolaevich Plotnikov, An Thyssen, Nicole Vaccaro, Jay Ariyawansa, Paul Bryan Burton. (2011) Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban. Journal of Cardiovascular Pharmacology 58:6, 581-588
CrossRef69
Nicolas Danchin, Etienne Puymirat, Tabassome Simon. (2011) A new victory for Greek philosophy. The Lancet 378:9809, e27
CrossRef70
Eugenia Nikolsky, Roxana Mehran, George D. Dangas, Jennifer Yu, Helen Parise, Ke Xu, Stuart J. Pocock, Gregg W. Stone. (2011) Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). The American Journal of Cardiology
CrossRef71
Leonardo Bolognese, Dominick J. Angiolillo. (2011) Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Current Opinion in Cardiology 26, S22-S30
CrossRef72
É. Bonnefoy, G. Kirkorian. (2011) La mortalité des syndromes coronariens aigus. Annales de Cardiologie et d'Angéiologie 60:6, 311-316
CrossRef73
M. Elbaz. (2011) Le rapport bénéfice-risque des nouveaux agents antiagrégants plaquettaires. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:203, 27-31
CrossRef74
Charles Knight, Adam D. Timmis. (2011) Almanac 2011: Acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia
CrossRef75
A. D. Michelson. (2011) Advances in Antiplatelet Therapy. Hematology 2011:1, 62-69
CrossRef76
J. Silvain, G. Cayla, J.-S. Hulot, J. Finzi, M. Kerneis, S. A. O'Connor, A. Bellemain-Appaix, O. Barthelemy, F. Beygui, J.-P. Collet, G. Montalescot. (2011) High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal
CrossRef77
Christian Weber, Heidi Noels. (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 17:11, 1410-1422
CrossRef78
M. Roffi, D. J. Angiolillo, A. P. Kappetein. (2011) Current concepts on coronary revascularization in diabetic patients. European Heart Journal 32:22, 2748-2757
CrossRef79
J. Oldgren, A. Budaj, C. B. Granger, Y. Khder, J. Roberts, A. Siegbahn, J. G. P. Tijssen, F. Van de Werf, L. Wallentin, . (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal 32:22, 2781-2789
CrossRef80
Zenon Huczek, Krzysztof J. Filipiak, Janusz Kochman, Marcin Michalak, Marek Roik, Marcin Grabowski, Grzegorz Opolski. (2011) Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. Platelets 22:7, 521-529
CrossRef81
Satyendra Giri. (2011) Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology
CrossRef82
Sukhdeep S. Basra, Peter Tsai, Nasser M. Lakkis. (2011) Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 58:22, 2263-2269
CrossRef83
Charles V. Pollack, Gerard X. Brogan, Marc Cohen, Deborah Diercks, Cindy Grines, Timothy D. Henry, Neal S. Kleiman, Robert P. Giugliano. (2011) ED to catheterization laboratory: a roundtable integrating trials with practice. The American Journal of Emergency Medicine 29:9, 1203-1216
CrossRef84
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology 58:23, 2432-2446
CrossRef85
David Iyú, Jackie R. Glenn, Ann E. White, Sue C. Fox, Natalia Dovlatova, Stan Heptinstall. (2011) P2Y 12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets 22:7, 504-515
CrossRef86
Johanne Silvain, Guillaume Cayla, Stephen A O’Connor, Jean-Philippe Collet, Gilles Montalescot. (2011) Antiplatelet options for secondary prevention in acute coronary syndromes. Expert Review of Cardiovascular Therapy 9:11, 1403-1415
CrossRef87
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology 27:6, S387-S401
CrossRef88
Sergio Coccheri. (2011) Antiplatelet therapy: Controversial aspects. Thrombosis Research
CrossRef89
Pamela Moceri, Denis Doyen, Pierre Cerboni, Emile Ferrari. (2011) Doubling the dose of Clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thrombosis Research 128:5, 458-462
CrossRef90
Stephen D. Wiviott, Willibald Hochholzer. (2011) On-Clopidogrel Platelet Reactivity. Journal of the American College of Cardiology 58:19, 1955-1957
CrossRef91
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef92
Matteo Nicola Dario Di Minno, Anna Guida, Marina Camera, Susanna Colli, Giovanni Di Minno, Elena Tremoli. (2011) Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. Annals of Medicine 43:7, 531-544
CrossRef93
Stefano De Servi, Eliano Pio Navarese, Maurizio D’Urbano, Stefano Savonitto. (2011) Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current Medical Research and Opinion 27:11, 2117-2122
CrossRef94
D. Divchev, C. Nienaber, H. Ince. (2011) Therapiestrategien beim akuten Koronarsyndrom und nach koronaren Interventionen. Der Internist 52:11, 1292-1300
CrossRef95
Somjot S. Brar, Jurrien ten Berg, Rossella Marcucci, Matthew J. Price, Marco Valgimigli, Hyo-Soo Kim, Giuseppe Patti, Nicoline J. Breet, Germano DiSciascio, Thomas Cuisset, George Dangas. (2011) Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:19, 1945-1954
CrossRef96
Thomas Cuisset, Jacques Quilici, Charlotte Grosdidier, Laurent Fourcade, Bénédicte Gaborit, Mathieu Pankert, Laurent Molines, Pierre-Emmanuel Morange, Jean Louis Bonnet, Marie-Christine Alessi. (2011) Comparison of Platelet Reactivity and Clopidogrel Response in Patients ≤75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Non–ST-Segment Elevation Acute Coronary Syndrome. The American Journal of Cardiology 108:10, 1411-1416
CrossRef97
Y. Li, H.-L. Tang, Y.-F. Hu, H.-G. Xie. (2011) The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients. Journal of Thrombosis and Haemostasisno-no
CrossRef98
L. Jacquin, J. -P. Auffray, J. Bessereau, A. Champenois, M. Ostorero, L. Bonello. (2011) Le ticagrelor dans les syndromes coronaires aigus : résultats de l’étude PLATO. Annales françaises de médecine d'urgence
CrossRef99
B. Riou. (2011) Des premiers pas de la thrombolyse préhospitalière à une prise en charge globale des syndromes coronariens aigus. Annales françaises de médecine d'urgence
CrossRef100
N. Assez, E. Wiel, C. Lemanski-Brulin, C. Adriansen, P. Goldstein. (2011) Syndromes coronariens aigus : prise en charge thérapeutique en urgence. Annales françaises de médecine d'urgence
CrossRef101
H. D. White. (2011) Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. European Heart Journal
CrossRef102
P. G. Steg, S. R. Mehta, J. W. Jukema, G. Y. H. Lip, C. M. Gibson, F. Kovar, P. Kala, A. Garcia-Hernandez, R. W. Renfurm, C. B. Granger, . (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal 32:20, 2541-2554
CrossRef103
Nalyaka Sambu, Nick Curzen. (2011) Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. British Journal of Clinical Pharmacology 72:4, 683-696
CrossRef104
Yanushi Dullewe Wijeyeratne, Stan Heptinstall. (2011) Anti-platelet therapy: ADP receptor antagonists. British Journal of Clinical Pharmacology 72:4, 647-657
CrossRef105
Antonio Tello-Montoliu, Salvatore D. Tomasello, Masafumi Ueno, Dominick J. Angiolillo. (2011) Antiplatelet therapy: thrombin receptor antagonists. British Journal of Clinical Pharmacology 72:4, 658-671
CrossRef106
S. Agewall, L. Badimon, L. Drouet, T. Eschenhagen, S. Husted, T. Simon, G. Steg. (2011) Oral antiplatelet agents in ACS: from pharmacology to clinical differences. Fundamental & Clinical Pharmacology 25:5, 564-571
CrossRef107
R. Teng, P. D. Mitchell, K. Butler. (2011) Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. Journal of Clinical Pharmacy and Therapeuticsno-no
CrossRef108
Inder M. Singh, David R. Holmes. (2011) Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. Current Problems in Cardiology 36:10, 375-401
CrossRef109
Dimitrios Alexopoulos, Ioanna Xanthopoulou, Panagiota Mylona, Angelos Perperis, Aggeliki Panagiotou, Gerasimos Dimitropoulos, Grigorios Tsigkas, George Hahalis, Periklis Davlouros. (2011) Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. Journal of Thrombosis and Thrombolysis 32:3, 328-333
CrossRef110
P. D. M. LEADBEATER, N. S. KIRKBY, S. THOMAS, A.-R. DHANJI, A. T. TUCKER, G. L. MILNE, J. A. MITCHELL, T. D. WARNER. (2011) Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. Journal of Thrombosis and Haemostasis 9:10, 2050-2056
CrossRef111
Adnan Kastrati, Robert A. Byrne, Stefanie Schulz. (2011) Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?. JACC: Cardiovascular Interventions 4:10, 1129-1132
CrossRef112
Giuseppe De Luca. (2011) Glycoprotein IIb-IIIa Inhibitors. Cardiovascular Therapeuticsno-no
CrossRef113
Neena S. Abraham. (2011) Prescribing proton pump inhibitor and clopidogrel together. Current Opinion in Gastroenterology 27:6, 558-564
CrossRef114
Timothy D. Warner, Sven Nylander, Carl Whatling. (2011) Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. British Journal of Clinical Pharmacology 72:4, 619-633
CrossRef115
Stephen L. Hauser, S. Claiborne Johnston. (2011) Global clinical trials: Challenges ahead. Annals of Neurology 70:4, A8-A9
CrossRef116
Axel Labriolle, Jean Philippe Doazan, Gilles Lemesle, Laurent Bonello. (2011) Genotypic and Phenotypic Assessment of Platelet Function and Response to P2Y12 Antagonists. Current Cardiology Reports 13:5, 439-450
CrossRef117
Paul A Gurbel, Young-Hoon Jeong, Udaya S Tantry. (2011) Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opinion on Investigational Drugs 20:10, 1445-1453
CrossRef118
José Antonio Páramo. (2011) Nueva era en la terapia antiplaquetar basada en los resultados de ensayos clínicos recientes. Medicina Clínica 137:11, 504-508
CrossRef119
Arun Kalyanasundaram, A. Michael Lincoff. (2011) Managing adverse effects and drug–drug interactions of antiplatelet agents. Nature Reviews Cardiology 8:10, 592-600
CrossRef120
D. J. Quinlan, J. W. Eikelboom, S. G. Goodman, R. C. Welsh, D. H. Fitchett, P. Theroux, S. R. Mehta. (2011) Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European Heart Journal 32:18, 2256-2265
CrossRef121
Cheol Whan Lee, Ilseon Hwang, Chan-Sik Park, Hyangsin Lee, Duk-Woo Park, Su-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Seong-Wook Park, Seung-Jung Park. (2011) Comparison of Differential Expression of P2Y12 Receptor in Culprit Coronary Plaques in Patients With Acute Myocardial Infarction Versus Stable Angina Pectoris. The American Journal of Cardiology 108:6, 799-803
CrossRef122
Marco Valgimigli, Monica Minarelli. (2011) Triple Antiplatelet Therapy in Acute Coronary Syndromes. Drugs 71:13, 1703-1719
CrossRef123
Corinne R. Fantz, Anne M. Winkler. (2011) Does Platelet Function Testing Predict Bleeding?-Pro. Point of Care: The Journal of Near-Patient Testing & Technology 10:3, 133-135
CrossRef124
R. F. STOREY, K. P. BLIDEN, R. ECOB, A. KARUNAKARAN, K. BUTLER, C. WEI, U. TANTRY, P. A. GURBEL. (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. Journal of Thrombosis and Haemostasis 9:9, 1730-1737
CrossRef125
Gianluca Campo, Matteo Miccoli, Matteo Tebaldi, Jlenia Marchesini, Luca Fileti, Monia Monti, Marco Valgimigli, Roberto Ferrari. (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:6, 399-407
CrossRef126
André Marette, Gary Sweeney. (2011) Cardiovascular complications of diabetes: recent insights in pathophysiology and therapeutics. Expert Review of Endocrinology & Metabolism 6:5, 689-696
CrossRef127
Thomas Cuisset, Jacques Quilici, William Cohen, Laurent Fourcade, Noémie Saut, Mathieu Pankert, Bénédicte Gaborit, Patrizia Carrieri, Pierre-Emmanuel Morange, Jean Louis Bonnet, Marie-Christine Alessi. (2011) Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. The American Journal of Cardiology 108:6, 760-765
CrossRef128
B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor, M. Alonso de Leciñana, J. Álvarez-Sabin, J. Arenillas, S. Calleja, I. Casado, M. Castellanos, J. Castillo, A. Dávalos, F. Díaz-Otero, J.A. Egido, J.C. López-Fernández, M. Freijo, A. García Pastor, F. Gilo, P. Irimia, J. Maestre, J. Masjuan, J. Martí-Fábregas, P. Martínez-Sánchez, E. Martínez-Vila, C. Molina, F. Nombela, M. Ribó, M. Rodríguez-Yañez, F. Rubio, J. Serena, P. Simal, J. Vivancos. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico. Neurología
CrossRef129
Nadia Paarup Dridi, Lene Holmvang, Peter Clemmensen. (2011) Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence. Clinical Investigation 1:9, 1315-1328
CrossRef130
Stephen O’Connor, Gilles Montalescot, Jean-Philippe Collet. (2011) The P2Y12 receptor as a target of antithrombotic drugs. Purinergic Signalling 7:3, 325-332
CrossRef131
David Lao, Andrew Boyle. 2011. Antithrombotic Therapy for Non-ST-Elevation Acute Coronary Syndrome. , 223-240.
CrossRef132
Alexander, John H., Lopes, Renato D., James, Stefan, Kilaru, Rakhi, He, Yaohua, Mohan, Puneet, Bhatt, Deepak L., Goodman, Shaun, Verheugt, Freek W., Flather, Marcus, Huber, Kurt, Liaw, Danny, Husted, Steen E., Lopez-Sendon, Jose, De Caterina, Raffaele, Jansky, Petr, Darius, Harald, Vinereanu, Dragos, Cornel, Jan H., Cools, Frank, Atar, Dan, Leiva-Pons, Jose Luis, Keltai, Matyas, Ogawa, Hisao, Pais, Prem, Parkhomenko, Alexander, Ruzyllo, Witold, Diaz, Rafael, White, Harvey, Ruda, Mikhail, Geraldes, Margarida, Lawrence, Jack, Harrington, Robert A., Wallentin, Lars, . (2011) Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine 365:8, 699-708
Full Text133
Abbie Edwards, Joseph A. Jakubowski, Andreas R. Rechner, Atsuhiro Sugidachi, Paul Harrison. (2011) Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y 12 blockade and influence of anticoagulant. Platelets1-10
CrossRef134
Tariq Ahmad, Deepak Voora, Richard C. Becker. (2011) The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nature Reviews Cardiology 8:10, 560-571
CrossRef135
Deepak Voora, Geoffrey S Ginsburg. (2011) Institutional Profile: A hub for bench-to-bedside pharmacogenomic-based research. Pharmacogenomics 12:8, 1095-1098
CrossRef136
Isabell Bernlochner, Robert A Byrne, Adnan Kastrati, Dirk Sibbing. (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy 9:8, 999-1014
CrossRef137
Hannes F. Alber, Kurt Huber, Otmar Pachinger, Matthias Frick. (2011) Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose?. Wiener klinische Wochenschrift 123:15-16, 468-476
CrossRef138
Masafumi Ueno, José L. Ferreiro, Salvatore D. Tomasello, Antonio Tello-Montoliu, Davide Capodanno, Naveen Seecheran, Murali Kodali, Kodlipet Dharmashankar, Bhaloo Desai, Ronald K. Charlton, Theodore A. Bass, Dominick J. Angiolillo. (2011) Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel. JACC: Cardiovascular Interventions 4:8, 905-912
CrossRef139
S A Scott, K Sangkuhl, E E Gardner, C M Stein, J-S Hulot, J A Johnson, D M Roden, T E Klein, A R Shuldiner. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics 90:2, 328-332
CrossRef140
P. G. Steg, K. Huber, F. Andreotti, H. Arnesen, D. Atar, L. Badimon, J.-P. Bassand, R. De Caterina, J. A. Eikelboom, D. Gulba, M. Hamon, G. Helft, K. A. A. Fox, S. D. Kristensen, S. V. Rao, F. W. A. Verheugt, P. Widimsky, U. Zeymer, J.-P. Collet. (2011) Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal 32:15, 1854-1864
CrossRef141
J. Donald Easton. (2011) Antithrombotic Management for Transient Ischemic Attack and Ischemic Stroke (Other than Atrial Fibrillation). Current Atherosclerosis Reports 13:4, 314-320
CrossRef142
Elise Camilleri, Laurent Jacquin, Franck Paganelli, Laurent Bonello. (2011) Personalized Antiplatelet Therapy: Review of the Latest Clinical Evidence. Current Cardiology Reports 13:4, 296-302
CrossRef143
Christopher W. Good, Peter B. Berger. (2011) P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When?. Current Cardiology Reports 13:4, 320-326
CrossRef144
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao. (2011) The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. Clinical Investigation 1:8, 1155-1165
CrossRef145
Lawrence Rajan, David J. Moliterno. (2011) Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?. Current Cardiology Reports 13:4, 303-311
CrossRef146
Giuseppe Biondi-Zoccai, Marzia Lotrionte, Pierfrancesco Agostoni, Antonio Abbate, Enrico Romagnoli, Giuseppe Sangiorgi, Dominick J. Angiolillo, Marco Valgimigli, Luca Testa, Fiorenzo Gaita, Imad Sheiban. (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology 150:3, 325-331
CrossRef147
Kathleen Butler, Renli Teng. (2011) Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. Current Medical Research and Opinion 27:8, 1585-1593
CrossRef148
Christoph Varenhorst, Sasha Koul, David Erlinge, Bo Lagerqvist, Agneta Siegbahn, Lars Wallentin, Stefan James. (2011) Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention—A case-control study. American Heart Journal 162:2, 363-371
CrossRef149
Renato D. Lopes, Richard C. Becker, John H. Alexander, Paul W. Armstrong, Robert M. Califf, Mark Y. Chan, Mark Crowther, Christopher B. Granger, Robert A. Harrington, Elaine M. Hylek, Stefan K. James, E. Marc Jolicoeur, Kenneth W. Mahaffey, L. Kristin Newby, Eric D. Peterson, Karen S. Pieper, Frans Werf, Lars Wallentin, Harvey D. White, Antonio C. Carvalho, Roberto R. Giraldez, Helio P. Guimaraes, Helena B. Nader, Renato A. K. Kalil, Joyce M. A. Bizzachi, Antonio C. Lopes, David A. Garcia. (2011) Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis 32:2, 242-266
CrossRef150
Henrik Sillén, Melanie Cook, Patty Davis. (2011) Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC–MS/MS. Journal of Chromatography B 879:23, 2315-2322
CrossRef151
Saissan Rajendran, Devang Parikh, Ibrahim Shugman, John K. French, Craig P. Juergens. (2011) High on Treatment Platelet Reactivity and Stent Thrombosis. Heart, Lung and Circulation 20:8, 525-531
CrossRef152
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef153
Dimitrios Alexopoulos. (2011) Prasugrel resistance: Fact or fiction. Platelets1-8
CrossRef154
Udaya S. Tantry, Paul A. Gurbel. (2011) Assessment of oral antithrombotic therapy by platelet function testing. Nature Reviews Cardiology 8:10, 572-579
CrossRef155
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef156
Harvey D White. (2011) Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. Current Opinion in Cardiology 26:4, 275-278
CrossRef157
Guang-Ming Tan, Yat-Yin Lam, Bryan P. Yan. (2011) Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome. Cardiovascular Therapeuticsno-no
CrossRef158
Michalis Hamilos, Olivier Muller, Argyrios Ntalianis, Catalina Trana, Jozef Bartunek, Giovanna Sarno, Fabio Mangiacapra, Karen Dierickx, Peter Meeus, Thomas Cuisset, Bernard Bruyne, William Wijns, Emanuele Barbato. (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. Journal of Thrombosis and Thrombolysis 32:1, 64-71
CrossRef159
D. Sibbing, W. Koch, S. Massberg, R. A. Byrne, J. Mehilli, S. Schulz, K. Mayer, I. Bernlochner, A. Schomig, A. Kastrati. (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European Heart Journal 32:13, 1605-1613
CrossRef160
E. P. Navarese, M. Verdoia, A. Schaffer, P. Suriano, M. Kozinski, F. Castriota, S. De Servi, J. Kubica, G. De luca. (2011) Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 104:7, 561-569
CrossRef161
Kevin P. Bliden, Udaya S. Tantry, Robert F. Storey, Young-Hoon Jeong, Martin Gesheff, Cheryl Wei, Paul A. Gurbel. (2011) The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal 162:1, 160-165
CrossRef162
Zeshan Qureshi, Alex R. Hobson. (2011) Clopidogrel “Resistance”: Where are We Now?. Cardiovascular Therapeuticsno-no
CrossRef163
Luis Carlos Saiz, Jesús Álvarez, Henar Martínez. (2011) Drug Regulatory Agencies’ Role in the Interaction Between Clopidogrel and Proton Pump Inhibitors. The American Journal of Gastroenterology 106:7, 1369-1370
CrossRef164
PH. G. STEG, S. H. DORMAN, P. AMARENCO. (2011) Atherothrombosis and the role of antiplatelet therapy. Journal of Thrombosis and Haemostasis 9, 325-332
CrossRef165
Hisao Ogawa, Seiji Hokimoto, Koichi Kaikita, Koichiro Yamamoto, Tadasuke Chitose, Takamichi Ono, Kenichi Tsujita. (2011) Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors. Journal of Cardiology 58:1, 6-17
CrossRef166
J.-J. Monsuez, H. Belbachir, A. Mahiou, K. Errhamouni, K. Tonyiga. (2011) Les traitements associés à la reperfusion des syndromes coronaires aigus avec sus-décalage de ST. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:199, 31-41
CrossRef167
Pierre Fontana, Pierre Albaladejo, Charles-Marc Samama. (2011) Gestion périopératoire des nouveaux antiplaquettaires. Le Praticien en Anesthésie Réanimation 15:3, 188-193
CrossRef168
Deepu Alexander, Allen Jeremias. (2011) Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opinion on Investigational Drugs 20:6, 849-857
CrossRef169
Igor Mrdovic, Lidija Savic, Gordana Krljanac, Milika Asanin, Jovan Perunicic, Ratko Lasica, Jelena Marinkovic, Nikola Kocev, Zorana Vasiljevic, Miodrag Ostojic. (2011) Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score. International Journal of Cardiology
CrossRef170
RADHAKRISHNAN RAMARAJ, MOHAMMAD REZA MOVAHED, MEHRNOOSH HASHEMZADEH. (2011) Novel Antiplatelet Agent Ticagrelor in the Management of Acute Coronary Syndrome. Journal of Interventional Cardiology 24:3, 199-207
CrossRef171
Mariano A Giorgi, Hernán Cohen Arazi, Claudio D Gonzalez, Guillermo Di Girolamo. (2011) Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opinion on Pharmacotherapy 12:8, 1285-1295
CrossRef172
Dominick J Angiolillo, Marco Roffi, Antonio Fernandez-Ortiz. (2011) Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. Expert Review of Cardiovascular Therapy 9:6, 697-710
CrossRef173
Stefano De Servi, Stefano Savonitto. (2011) How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial?. International Journal of Cardiology 149:2, 265-267
CrossRef174
M. J. Chapman, H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, A. L. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, B. G. Nordestgaard, K. K. Ray, Z. Reiner, M.-R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, G. F. Watts, . (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:11, 1345-1361
CrossRef175
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef176
Daniel J. Crespin, Jerome J. Federspiel, Andrea K. Biddle, Daniel E. Jonas, Joseph S. Rossi. (2011) Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Value in Health 14:4, 483-491
CrossRef177
W. Motz, W. Kerner. (2011) Kardiale Endorganschäden bei Diabetes. Der Internist 52:5, 505-517
CrossRef178
M. Oberhänsli, S. Puricel, M. Togni, S. Cook. (2011) Koronare Stent-Thrombosen. Herz 36:3, 241-253
CrossRef179
Xiao-dong Wang, Dai-fu Zhang, Shao-wei Zhuang, Yan Lai. (2011) Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance. Clinical Cardiology 34:5, 332-338
CrossRef180
Davide Capodanno, Corrado Tamburino, George Dangas. (2011) The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 12:7, 1075-1086
CrossRef181
Thomas Gremmel, Sabine Steiner, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christoph W. Kopp. (2011) A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. International Journal of Cardiology
CrossRef182
Stefan Lischke, David J Schneider. (2011) Recent developments in the use of antiplatelet agents to prevent cardiovascular events. Future Cardiology 7:3, 403-413
CrossRef183
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef184
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef185
Michael A. Burke, Richard Lee, Dan J. Fintel. (2011) Early clopidogrel use in non–ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. American Heart Journal 161:5, 832-841
CrossRef186
Emma D. Deeks. (2011) Ticagrelor. Drugs 71:7, 909-933
CrossRef187
Jeremy S. Paikin, Doug S. Wright, John W. Eikelboom. (2011) Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. Blood Reviews 25:3, 123-129
CrossRef188
G. Y. H. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, E. Knight, D. A. Lane, M. Levi, F. Marin, G. Palareti, P. Kirchhof, , J.-P. Collet, A. Rubboli, D. Poli, J. Camm. (2011) Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 13:5, 723-746
CrossRef189
Peter Bach, Jonas Boström, Kay Brickmann, J.J.J. van Giezen, Ragnar Hovland, Annika U. Petersson, Asim Ray, Fredrik Zetterberg. (2011) A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor. Bioorganic & Medicinal Chemistry Letters 21:10, 2877-2881
CrossRef190
Benjamin M. Scirica, Christopher P. Cannon, Håkan Emanuelsson, Eric L. Michelson, Robert A. Harrington, Steen Husted, Stefan James, Hugo Katus, Prem Pais, Dimitar Raev, Jindrich Spinar, Ph. Gabriel Steg, Robert F. Storey, Lars Wallentin. (2011) The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American College of Cardiology 57:19, 1908-1916
CrossRef191
Antonio Tello-Montoliu, Masafumi Ueno, Dominick J Angiolillo. (2011) Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology 7:3, 381-402
CrossRef192
R. A. Ajjan, Peter J. Grant. (2011) The Role of Antiplatelets in Hypertension and Diabetes Mellitus. The Journal of Clinical Hypertension 13:4, 305-313
CrossRef193
Amelia Carro, Rachel Bastiaenen, Juan Carlos Kaski. (2011) Age Related Issues in Reperfusion of Myocardial Infarction. Cardiovascular Drugs and Therapy 25:2, 139-148
CrossRef194
Renato D. Lopes. (2011) Antiplatelet agents in cardiovascular disease. Journal of Thrombosis and Thrombolysis 31:3, 306-309
CrossRef195
Giuseppe Patti, Vincenzo Pasceri, Vincenzo Vizzi, Elisabetta Ricottini, Germano Di Sciascio. (2011) Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). The American Journal of Cardiology 107:7, 995-1000
CrossRef196
Seung-Jung Park, Duk-Woo Park, Jun-Hyok Oh. (2011) Antiplatelet therapy in elderly patients. Aging Health 7:2, 311-320
CrossRef197
ROBERT P. GIUGLIANO, CHARLES V POLLACK Jr., GERARD X BROGAN Jr., MARC COHEN, DEBORAH B DIERCKS, CINDY L GRINES, TIMOTHY D. HENRY, NEAL S KLEIMAN. (2011) Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. Journal of Interventional Cardiology 24:2, 119-136
CrossRef198
In-Suk Kim, Young-Hoon Jeong, Yongwhi Park, Ki-Soo Park, Seong-Eun Yun, Jeong-Rang Park, Seok-Jae Hwang, Eun-Ha Koh, Choong Hwan Kwak, Jin-Yong Hwang, Sunjoo Kim. (2011) Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype. JACC: Cardiovascular Interventions 4:4, 381-391
CrossRef199
Charles Brown, Brijen Joshi, Nauder Faraday, Ashish Shah, David Yuh, Jeffrey J. Rade, Charles W. Hogue. (2011) Emergency Cardiac Surgery in Patients with Acute Coronary Syndromes. Anesthesia & Analgesia 112:4, 777-799
CrossRef200
Udaya S. Tantry, Dean J. Kereiakes, Paul A. Gurbel. (2011) Clopidogrel and Proton Pump Inhibitors. JACC: Cardiovascular Interventions 4:4, 365-380
CrossRef201
Michelle T. Martin, Sarah A. Spinler, Edith A. Nutescu. (2011) Emerging Antiplatelet Therapies in Percutaneous Coronary Intervention: A Focus on Prasugrel. Clinical Therapeutics 33:4, 425-442
CrossRef202
Maria M. Wanitschek, Otmar Pachinger, Hannes F. Alber. (2011) Akutes Koronarsyndrom. Wiener klinisches Magazin 14:2, 8-14
CrossRef203
Kurt Huber, Bashar Hamad, Peter Kirkpatrick. (2011) Ticagrelor. Nature Reviews Drug Discovery 10:4, 255-256
CrossRef204
Philippe Kolh, William Wijns. (2011) Joint ESC/EACTS guidelines on myocardial revascularization. Journal of Cardiovascular Medicine 12:4, 264-267
CrossRef205
Thomas D Stuckey, Bruce R Brodie. (2011) Outcomes with drug-eluting stents in diabetic patients. Interventional Cardiology 3:2, 235-245
CrossRef206
Edward L. Korn, Boris Freidlin. (2011) Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report. The American Journal of Bioethics 11:3, 2-10
CrossRef207
Andrea Rubboli. (2011) The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update. Internal and Emergency Medicine
CrossRef208
Victor A. Ferraris, Jeremiah R. Brown, George J. Despotis, John W. Hammon, T. Brett Reece, Sibu P. Saha, Howard K. Song, Ellen R. Clough, Linda J. Shore-Lesserson, Lawrence T. Goodnough, C. David Mazer, Aryeh Shander, Mark Stafford-Smith, Jonathan Waters, Robert A. Baker, Timothy A. Dickinson, Daniel J. FitzGerald, Donald S. Likosky, Kenneth G. Shann. (2011) 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
The International Consortium for Evidence Based Perfusion formally endorses these guidelines.. The Annals of Thoracic Surgery 91:3, 944-982
CrossRef209
Udaya S Tantry, Dean J Kereiakes, Paul A Gurbel. (2011) Role of ticagrelor in the treatment of coronary artery disease. Clinical Investigation 1:3, 429-437
CrossRef210
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, A. Graham Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology 27:2, 208-221
CrossRef211
Nikolaus Sarafoff, Lydia Neumann, Tanja Morath, Isabell Bernlochner, Julinda Mehilli, Albert Schömig, Adnan Kastrati, Dirk Sibbing. (2011) Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. American Heart Journal 161:3, 605-610
CrossRef212
Harvey D. White. (2011) Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. American Heart Journal 161:3, 450-461
CrossRef213
B. Gellen, E. Teiger. (2011) Thrombose de stent. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:196, 31-34
CrossRef214
James J. Nawarskas, Sara M. Clark. (2011) Ticagrelor. Cardiology in Review 19:2, 95-100
CrossRef215
Samir B. Damani, Eric J. Topol. (2011) Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 3:2, 206-215
CrossRef216
Nigel J Kent, Sinead O'Brien, Lourdes Basabe-Desmonts, Gerardene R Meade, Brian D MacCraith, Brian G Corcoran, Dermot Kenny, Antonio J Ricco. (2011) Shear-Mediated Platelet Adhesion Analysis in Less Than 100 μ L of Blood: Toward a POC Platelet Diagnostic. IEEE Transactions on Biomedical Engineering 58:3, 826-830
CrossRef217
Philip Urban, Alexandre Abizaid, Adrian Banning, Antonio L. Bartorelli, Ana Cebrian Baux, Vladimír Džavík, Stephen Ellis, Runlin Gao, David Holmes, Myung Ho Jeong, Victor Legrand, Franz-Josef Neumann, Maria Nyakern, Christian Spaulding, Stephen Worthley. (2011) Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. Journal of the American College of Cardiology 57:13, 1445-1454
CrossRef218
Benjamin Z. Galper, Jennifer Stant, Mireya Reilly, Sondra Walter, Michael Collins, Osman Sayan, Gerald Neuberg, Leslie Miller, Jeffery W. Moses, Gregg W. Stone, James Giglio, LeRoy E. Rabbani. (2011) Updating the Chest Pain Algorithm. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 10:1, 9-16
CrossRef219
M. Cattaneo. (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:7, 2102-2112
CrossRef220
K. M. MUSALLAM, K. CHARAFEDDINE, A. BITAR, M. KHOURY, S. ASSAAD, J. BERESIAN, S. ALAM, A. T. TAHER. (2011) Resistance to aspirin and clopidogrel therapy. International Journal of Laboratory Hematology 33:1, 1-18
CrossRef221
Andreas Eisenreich, Ursula Rauch. (2011) PI3K Inhibitors in Cardiovascular Disease. Cardiovascular Therapeutics 29:1, 29-36
CrossRef222
Joshua P Leitner, Jinnette Dawn Abbott. (2011) Drug-eluting stents and glycoprotein IIbIIIa inhibitors in the pharmacoinvasive management of ST elevation MI. Interventional Cardiology 3:1, 17-21
CrossRef223
Tracy Y. Wang, Antonio Gutierrez, Eric D. Peterson. (2011) Percutaneous coronary intervention in the elderly. Nature Reviews Cardiology 8:2, 79-90
CrossRef224
Marco Cattaneo. (2011) Resistance to anti-platelet agents. Thrombosis Research 127, S61-S63
CrossRef225
Fiona Foo, Keith G Oldroyd. (2011) Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine 5:1, 9-30
CrossRef226
David J. Schneider. (2011) Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor Therapy
CrossRef227
James A Shand, Ian BA Menown, Robert F Storey. (2011) Ticagrelor: from concept to clinical evaluation. Biomarkers in Medicine 5:1, 53-62
CrossRef228
Soochong Kim, Satya P. Kunapuli. (2011) P2Y12 receptor in platelet activation. Platelets 22:1, 54-58
CrossRef229
Claes Held, Nils Åsenblad, Jean Pierre Bassand, Richard C. Becker, Christopher P. Cannon, Marc J. Claeys, Robert A. Harrington, Jay Horrow, Steen Husted, Stefan K. James, Kenneth W. Mahaffey, José C. Nicolau, Benjamin M. Scirica, Robert F. Storey, Marius Vintila, Joseph Ycas, Lars Wallentin. (2011) Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 57:6, 672-684
CrossRef230
A Maeda, H Ando, T Asai, H Ishiguro, N Umemoto, M Ohta, M Morishima, A Sumida, T Kobayashi, K Hosohata, K Ushijima, A Fujimura. (2011) Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Clinical Pharmacology & Therapeutics 89:2, 229-233
CrossRef231
Dimitrios Alexopoulos. (2011) CYP2C19*2 allele: guiding medication choice after percutaneous coronary intervention. Interventional Cardiology 3:1, 1-4
CrossRef232
Nicholas L.M. Cruden, Kristin Morch, Daniel R. Wong, W. Peter Klinke, John Ofiesh, J. David Hilton. (2011) Clopidogrel loading dose and bleeding outcomes in patients undergoing urgent coronary artery bypass grafting. American Heart Journal 161:2, 404-410
CrossRef233
Charles-Marc Samama. (2011) Gestion péri–opératoire des antiplaquettaires et des anticoagulants. Revue Francophone des Laboratoires 2011:429, 17-19
CrossRef234
Richard Hall, C. David Mazer. (2011) Antiplatelet Drugs. Anesthesia & Analgesia 112:2, 292-318
CrossRef235
Ada Stefanescu, Stephen D. Wiviott. (2011) Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports 5:1, 86-95
CrossRef236
C. HÖGBERG, O. GIDLÖF, C. TAN, S. SVENSSON, J. NILSSON-ÖHMAN, D. ERLINGE, B. OLDE. (2011) Succinate independently stimulates full platelet activation via cAMP and phosphoinositide 3-kinase-β signaling. Journal of Thrombosis and Haemostasis 9:2, 361-372
CrossRef237
E. Ferrari. (2011) Syndrome coronarien : risques ischémiques et risques hémorragiques. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:195, 28-30
CrossRef238
Matthew J Price, Colin M Barker. (2011) Functional testing methods for the antiplatelet effect of P2Y 12 receptor antagonists. Biomarkers in Medicine 5:1, 43-51
CrossRef239
Jean-Sébastien Hulot, Jean-Philippe Collet, Gilles Montalescot. (2011) Genetic substudy of the PLATO trial. The Lancet 377:9766, 637
CrossRef240
M. Cattaneo. (2011) Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and Haemostasis 105:Suppl. 1, S67-S74
CrossRef241
I. Tentzeris, J. Siller-Matula, S. Farhan, R. Jarai, J. Wojta, K. Huber. (2011) Platelet function variability and non-genetic causes. Thrombosis and Haemostasis 105:Suppl. 1, S60-S66
CrossRef242
S. Ylä-Herttuala, J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, J. W. Jukema, R. Krams, B. R. Kwak, N. Marx, M. Naruszewicz, A. Newby, G. Pasterkamp, P. W. J. C. Serruys, J. Waltenberger, C. Weber, L. Tokgözoglu. (2011) Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis 106:1, 1-19
CrossRef243
G. Y. H. Lip, F. Andreotti, L. Fauchier, K. Huber, E. Hylek, E. Knight, D. Lane, M. Levi, F. Marín, G. Palareti, P. Kirchhof. (2011) Bleeding risk assessment and management in atrial fibrillation patients. Thrombosis and Haemostasis 106:6, 997-1011
CrossRef244
Masafumi Ueno, Murali Kodali, Antonio Tello-Montoliu, Dominick Joseph Angiolillo. (2011) Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis 18:6, 431-442
CrossRef245
B. Ivandic, N. Frey. (2011) New approaches and indications for the analysis of platelet function in cardiology. Hämostaseologie 31:2, 73-76
CrossRef246
R. F. Storey. (2011) Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and Haemostasis 105:Suppl. 1, S75-S81
CrossRef247
Victor L. Serebruany. (2011) The FDA Outlook of Events Reporting after Ticagrelor or Clopidogrel in the PLATO Trial: Impact of Sponsor Censoring Dates, Drug Discontinuation, and Withdrawal of Consent. Cardiology 120:3, 169-171
CrossRef248
D. Sibbing, R. A. Byrne, I. Bernlochner, A. Kastrati. (2011) High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis 106:2, 191-202
CrossRef249
Manuel Piqué, Isabel Hernández, Antonio Miñano, Fernando Worner Diz. (2011) Administración upstream de inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: la estrategia TACTICS. Revista Española de Cardiología Suplementos 11, 27-32
CrossRef250
V. L. Serebruany. (2011) Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis 105:5, 752-759
CrossRef251
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef252
Nicholaos Kakouros, Jeffrey J. Rade, Antonios Kourliouros, Jon R. Resar. (2011) Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective. International Journal of Endocrinology 2011, 1-14
CrossRef253
D. J. Angiolillo, P. Capranzano, J. L. Ferreiro, M. Ueno, D. Capodanno, K. Dharmashankar, A. Darlington, S. Sumner, B. Desai, R. K. Charlton, L. C. Box, M. Zenni, L. A. Guzman, T. A. Bass. (2011) Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thrombosis and Haemostasis 106:2, 253-262
CrossRef254
M. Orban, R. A. Byrne, J. Hausleiter, K.-L. Laugwitz, D. Sibbing. (2011) Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and Haemostasis 106:3, 555-558
CrossRef255
José Luis Ferreiro, Joan Antoni Gómez-Hospital, Dominick J. Angiolillo, Ángel Cequier. (2011) ¿Los nuevos antagonistas del receptor P2Y12 pueden reemplazar a los inhibidores de la glucoproteína IIb/IIIa?. Revista Española de Cardiología Suplementos 11, 14-19
CrossRef256
D. P. Faxon, J. W. Eikelboom, P. B. Berger, D. R. Holmes, D. L. Bhatt, D. J. Moliterno, R. C. Becker, D. J. Angiolillo. (2011) Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis 106:4, 572-584
CrossRef257
Wei C Lau, Terrence D Welch, Theresa Shields, Melvyn Rubenfire, Udaya S Tantry, Paul A Gurbel. (2011) The Effect of St Johnʼs Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. Journal of Cardiovascular Pharmacology 57:1, 86-93
CrossRef258
Peter Damman, Marcel A.M. Beijk, Wichert J. Kuijt, Niels J.W. Verouden, Nan van Geloven, José P.S. Henriques, Jan Baan, Marije M. Vis, Martijn Meuwissen, Jan P. van Straalen, Johan Fischer, Karel T. Koch, Jan J. Piek, Jan G.P. Tijssen, Robbert J. de Winter. (2011) Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:1, 29-36
CrossRef259
W. Korte, M. Cattaneo, P.-G. Chassot, S. Eichinger, C. von Heymann, N. Hofmann, H. Rickli, M. Spannagl, B. Ziegler, F. Verheugt, K. Huber. (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease. Thrombosis and Haemostasis 105:5, 743-749
CrossRef260
David Erlinge. 2011. P2Y Receptors in Health and Disease. , 417-439.
CrossRef261
Marc Buyse, Ian C. Marschner. (2011) Assessment of Statistical Heterogeneity in the PLATO Trial. Cardiology 118:2, 138-138
CrossRef262
T. Ben Morrison, Brian M. Horst, Michael J. Brown, Malcolm R. Bell, Paul R. Daniels. (2011) Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef263
Harold P. Adams, Patricia H. Davis. 2011. Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. , 971-991.
CrossRef264
David P. Faxon. (2011) Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef265
P. W. Radke, H. Schunkert. (2010) Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. European Heart Journal 31:24, 2971-2973
CrossRef266
S. James, D. J. Angiolillo, J. H. Cornel, D. Erlinge, S. Husted, F. Kontny, J. Maya, J. C. Nicolau, J. Spinar, R. F. Storey, S. R. Stevens, L. Wallentin, . (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal 31:24, 3006-3016
CrossRef267
Savanna Steele, Craig R Lee. (2010) Research Highlights. Pharmacogenomics 11:12, 1687-1690
CrossRef268
Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling, Gordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 56:24, 2051-2066
CrossRef269
Kamala Bhavaraju, Alexander Georgakis, Jianguo Jin, Theodore Kent Gartner, Yoshiaki Tomiyama, Alan Nurden, Paquita Nurden, Satya P. Kunapuli. (2010) Antagonism of P2Y 12 reduces physiological thromboxane levels. Platelets 21:8, 604-609
CrossRef270
L. Drouet, C. Bal dit Sollier, P. Henry. (2010) Antiagrégants plaquettaires et diabète. Annales de Cardiologie et d'Angéiologie 59, S56-S64
CrossRef271
Syed A Raza, Wanda M Popescu, Ion S Jovin. (2010) Perioperative stent thrombosis. Interventional Cardiology 2:6, 821-828
CrossRef272
P. Aubry, X. Halna du Fretay. (2010) Traitements antithrombotiques du syndrome coronarien aigu avec sus-décalage ST. Annales de Cardiologie et d'Angéiologie 59:6, 335-343
CrossRef273
Joakim Alfredsson, Eva Swahn. (2010) Management of acute coronary syndromes from a gender perspective. Fundamental & Clinical Pharmacology 24:6, 719-728
CrossRef274
P. Barash, S. Akhtar. (2010) Coronary stents: factors contributing to perioperative major adverse cardiovascular events. British Journal of Anaesthesia 105:Supplement 1, i3-i15
CrossRef275
Robert P. Giugliano, Eugene Braunwald. (2010) The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 56:25, 2126-2138
CrossRef276
Wiebke Gogarten, Erik Vandermeulen, Hugo Van Aken, Sibylle Kozek, Juan V Llau, Charles M Samama. (2010) Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology 27:12, 999-1015
CrossRef277
Neena S Abraham, Mark A Hlatky, Elliott M Antman, Deepak L Bhatt, David J Bjorkman, Craig B Clark, Curt D Furberg, David A Johnson, Charles J Kahi, Loren Laine, Kenneth W Mahaffey, Eamonn M Quigley, James Scheiman, Laurence S Sperling, Gordon F Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 105:12, 2533-2549
CrossRef278
V. Wenzel, S.G. Russo, H.R. Arntz, J. Bahr, M.A. Baubin, B.W. Böttiger, B. Dirks, U. Kreimeier, M. Fries, C. Eich. (2010) Kommentar zu den Leitlinien 2010 zur kardiopulmonalen Reanimation des European Resuscitation Council. Der Anaesthesist 59:12, 1105-1123
CrossRef279
L. Lorgis, C. Richard, M. Zeller, A. Gudjoncik, P. Buffet, I. L’Huillier, Y. Cottin. (2010) Les anti-agrégants plaquettaires au cours du syndrome coronarien aigu. Données des grandes études. Annales de Cardiologie et d'Angéiologie 59, S47-S55
CrossRef280
Elias B. Hanna, Sunil V. Rao, Steven V. Manoukian, Jorge F. Saucedo. (2010) The Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:12, 1209-1219
CrossRef281
Bhatt, Deepak L., Cryer, Byron L., Contant, Charles F., Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J., Shook, Thomas L., Lapuerta, Pablo, Goldsmith, Mark A., Laine, Loren, Scirica, Benjamin M., Murphy, Sabina A., Cannon, Christopher P., . (2010) Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine 363:20, 1909-1917
Full Text282
J. Silvain, A. Pena, G. Cayla, D. Brieger, A. Bellemain-Appaix, T. Chastre, J.-B. Vignalou, F. Beygui, O. Barthelemy, J.-P. Collet, G. Montalescot. (2010) Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. European Heart Journal 31:22, 2816-2821
CrossRef283
Stephen D. Wiviott, Jessica L. Mega. (2010) Another Step on the Road to Tailored Antiplatelet Therapy
CrossRef284
S. Goto, H. Ogawa, M. Takeuchi, M. D. Flather, D. L. Bhatt, . (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. European Heart Journal 31:21, 2601-2613
CrossRef285
Chadi Dib, Elias B. Hanna, Mazen S. Abu-Fadel. (2010) A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome. The American Journal of the Medical Sciences 340:5, 407-411
CrossRef286
H.-R. Arntz, L.L. Bossaert, N. Danchin, N. Nicolau. (2010) Initiales Management des akuten Koronarsyndroms. Notfall + Rettungsmedizin 13:7, 621-634
CrossRef287
Sébastien Arméro, Laurence Camoin Jau, Omar Aït Mokhtar, Julien Mancini, Caroline Burignat-Bonello, Iliassou Tahirou, Stéphane Arques, Françoise Dignat-George, Franck Paganelli, Laurent Bonello. (2010) Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 21:7, 503-507
CrossRef288
Jolanta M Siller-Matula, Bernd Jilma. (2010) Ticagrelor: from discovery to Phase III clinical trial. Future Cardiology 6:6, 753-764
CrossRef289
Anne Bellemain-Appaix, David Brieger, Farzin Beygui, Johanne Silvain, Ana Pena, Guillaume Cayla, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot. (2010) New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:19, 1542-1551
CrossRef290
Felicita Andreotti, Teodosio Pafundi. (2010) Los nuevos anticoagulantes y el futuro de la cardiología. Revista Española de Cardiología 63:11, 1223-1229
CrossRef291
Nina S. Huang, Huzefa H. Master, Julie A. Fusco, Zoon H. Park. (2010) Ticagrelor: A Novel Oral Antiplatelet Agent. The Consultant Pharmacist 25:11, 745-755
CrossRef292
Guido Parodi, Giuseppe Luca, Guia Moschi, Benedetta Bellandi, Renato Valenti, Angela Migliorini, Nazario Carrabba, David Antoniucci. (2010) Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. Journal of Thrombosis and Thrombolysis 30:4, 446-451
CrossRef293
Fabio Mangiacapra, Olivier Muller, Argyrios Ntalianis, Catalina Trana, Guy R. Heyndrickx, Jozef Bartunek, Marc Vanderheyden, William Wijns, Bernard De Bruyne, Emanuele Barbato. (2010) Comparison of 600 Versus 300-mg Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Angioplasty. The American Journal of Cardiology 106:9, 1208-1211
CrossRef294
Thomas Cuisset, Corinne Frere, Pierre Julien Moro, Jacques Quilici, Coline Pons, Bénédicte Gaborit, Laurence Camoin, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi. (2010) Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thrombosis Research 126:5, e400-e402
CrossRef295
Davide Capodanno, Dominick J. Angiolillo. (2010) Antithrombotic Therapy in the Elderly. Journal of the American College of Cardiology 56:21, 1683-1692
CrossRef296
Jean-Luc Reny, Robert F. Bonvini, John M. Bonvini, Marco Roffi, Pierre Fontana. (2010) Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. Cardiovascular Therapeuticsno-no
CrossRef297
I. Cornelissen, D. Palmer, T. David, L. Wilsbacher, C. Concengco, P. Conley, A. Pandey, S. R. Coughlin. (2010) Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proceedings of the National Academy of Sciences 107:43, 18605-18610
CrossRef298
, , W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M. F. Piepoli, C. Pirlet, J. L. Pomar, N. Reifart, F. L. Ribichini, M. J. Schalij, P. Sergeant, P. W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. Kolh, O. Alfieri, J. Dunning, S. Elia, P. Kappetein, U. Lockowandt, G. Sarris, P. Vouhe, , P. Kearney, L. von Segesser, S. Agewall, A. Aladashvili, D. Alexopoulos, M. J. Antunes, E. Atalar, A. Brutel de la Riviere, A. Doganov, J. Eha, J. Fajadet, R. Ferreira, J. Garot, J. Halcox, Y. Hasin, S. Janssens, K. Kervinen, G. Laufer, V. Legrand, S. A. M. Nashef, F.-J. Neumann, K. Niemela, P. Nihoyannopoulos, M. Noc, J. J. Piek, J. Pirk, Y. Rozenman, M. Sabate, R. Starc, M. Thielmann, D. J. Wheatley, S. Windecker, M. Zembala. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 31:20, 2501-2555
CrossRef299
Young-Hoon Jeong, Jung-Hyun Cho, Min-Kyung Kang, Jin-Sin Koh, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thrombosis Research 126:4, e334-e338
CrossRef300
Michael A. Gaglia, Steven V. Manoukian, Ron Waksman. (2010) Novel antiplatelet therapy. American Heart Journal 160:4, 595-604
CrossRef301
Emmanouil S Brilakis, Subhash Banerjee. (2010) Management of patients with coronary stents in the ICU. Current Opinion in Critical Care 16:5, 426-431
CrossRef302
Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan J Barratt, Jay Horrow, Steen Husted, Hugo Katus, P Gabriel Steg, Svati H Shah, Richard C Becker. (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet 376:9749, 1320-1328
CrossRef303
Sergio Leonardi, Pierluigi Tricoci, Richard C. Becker. (2010) Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Drugs 70:14, 1771-1783
CrossRef304
Gianluca Campo, Luca Fileti, Marco Valgimigli, Matteo Tebaldi, Elisa Cangiano, Caterina Cavazza, Jlenia Marchesini, Roberto Ferrari. (2010) Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis 30:3, 319-331
CrossRef305
Zuzana Motovska, Jiri Knot, Petr Widimsky. (2010) REVIEW: Stent Thrombosis-Risk Assessment and Prevention. Cardiovascular Therapeutics 28:5, e92-e100
CrossRef306
Christopher Ombrello, Robert C. Block, Craig N. Morrell. (2010) Our Expanding View of Platelet Functions and Its Clinical Implications. Journal of Cardiovascular Translational Research 3:5, 538-546
CrossRef307
Pier Mannuccio Mannucci, Massimo Franchini. (2010) New antiplatelet agents in acute coronary syndromes (ACS): An update. European Journal of Internal Medicine 21:5, 465-466
CrossRef308
Wei Feng Lu, Wei Mo, Zhenjie Liu, Wei Guo Fu, Da Qiao Guo, Yu Qi Wang, Hou Yan Song. (2010) The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Thrombosis Research 126:4, e339-e343
CrossRef309
Robert F. Storey, Dominick J. Angiolillo, Shankar B. Patil, Bhaloo Desai, Rosemary Ecob, Steen Husted, Hakan Emanuelsson, Christopher P. Cannon, Richard C. Becker, Lars Wallentin. (2010) Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 56:18, 1456-1462
CrossRef310
Marco Cattaneo, Gian Marco Podda. (2010) State of the art of new P2Y12 antagonists. Internal and Emergency Medicine 5:5, 385-391
CrossRef311
Leo Bossaert, Robert E. O’Connor, Hans-Richard Arntz, Steven C. Brooks, Deborah Diercks, Gilson Feitosa-Filho, Jerry P. Nolan, Terry L. Vanden Hoek, Darren L. Walters, Aaron Wong, Michelle Welsford, Karen Woolfrey. (2010) Part 9: Acute coronary syndromes. Resuscitation 81:1, e175-e212
CrossRef312
Betti Giusti, Rosanna Abbate. (2010) Response to antiplatelet treatment: from genes to outcome. The Lancet 376:9749, 1278-1281
CrossRef313
Łukasz A Małek, Adam Witkowski. (2010) Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. Interventional Cardiology 2:5, 705-718
CrossRef314
Hans-Richard Arntz, Leo L. Bossaert, Nicolas Danchin, Nikolaos I. Nikolaou. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 81:10, 1353-1363
CrossRef315
Xavier Bosch, Jaume Marrugat, Juan Sanchis, Xavier Bosch. 2010. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef316
Fuster, Valentin, . (2010) Fine-Tuning Therapy for Acute Coronary Syndromes. New England Journal of Medicine 363:10, 976-977
Full Text317
The CURRENT–OASIS 7 Investigators. (2010) Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine 363:10, 930-942
Full Text318
Laurent Bonello, Udaya S. Tantry, Rossella Marcucci, Ruediger Blindt, Dominick J. Angiolillo, Richard Becker, Deepak L. Bhatt, Marco Cattaneo, Jean Philippe Collet, Thomas Cuisset, Christian Gachet, Gilles Montalescot, Lisa K. Jennings, Dean Kereiakes, Dirk Sibbing, Dietmar Trenk, Jochem W. Van Werkum, Franck Paganelli, Matthew J. Price, Ron Waksman, Paul A. Gurbel. (2010) Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology 56:12, 919-933
CrossRef319
Henrik Sillén, Melanie Cook, Patty Davis. (2010) Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. Journal of Chromatography B 878:25, 2299-2306
CrossRef320
Deepak L. Bhatt. (2010) Acute coronary syndrome update for hospitalists. Journal of Hospital Medicine 5:S4, S15-S21
CrossRef321
Deepak Thomas, Robert P. Giugliano. (2010) Perspectives on the 2009 Focused Updates on the Management of ST-Segment Elevation Myocardial Infarction and Percutaneous Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:3, 126-133
CrossRef322
Matthias Orth, Alexander Eduard Rosler. (2010) Thrombozytenhemmende Therapie in der Kardiologie: aktuelle Entwicklungen bei Therapie und Monitoring / Antiplatelet drugs in cardiology: current trends in therapy and monitoring. LaboratoriumsMedizin 34:5, 261-269
CrossRef323
P. Aguiar-Souto, S. Raposeiras-Roubín, J.R. González-Juanatey. (2010) Novedades en el último año en el planteamiento terapéutico de la cardiopatía hipertensiva, de la cardiopatía isquémica y de la fibrilación auricular. Revista Clínica Española 210, 2-11
CrossRef324
Jeremy S. Paikin, John W. Eikelboom, John A. Cairns, Jack Hirsh. (2010) New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology 7:9, 498-509
CrossRef325
Gregory D. Trachiotis. (2010) Early Antiplatelet Therapy in Coronary Artery Bypass Grafting. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 5:5, 317-325
CrossRef326
Elisabeth Mahla, Helfried Metzler, Udaya S. Tantry, Paul A. Gurbel. (2010) Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. The Annals of Thoracic Surgery 90:3, 1040-1051
CrossRef327
A. W. J. van 't Hof. (2010) Early and aggressive treatment of patients with ST-segment elevation myocardial infarction: deciphering recent clinical trials and the timing of optimal platelet inhibition. European Heart Journal Supplements 12:Suppl D, D24-D35
CrossRef328
Matthias Orth, Alexander Eduard Rosler. (2010) Antiplatelet drugs in cardiology: current trends in therapy and monitoring 1. LaboratoriumsMedizin 34:5, ---
CrossRef329
M. Valgimigli. (2010) Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome. European Heart Journal Supplements 12:Suppl D, D14-D23
CrossRef330
Fabio Mangiacapra, Emanuele Barbato. (2010) Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure & Cardiovascular Prevention 17:3, 121-130
CrossRef331
John Jason Sutton, Colin M. Barker. (2010) Is There a Role for Platelet Function Testing for Patients on Chronic Dual Antiplatelet Therapy?. Current Cardiovascular Risk Reports 4:5, 327-331
CrossRef332
J. David Spence. (2010) Secondary stroke prevention. Nature Reviews Neurology
CrossRef333
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Review of Cardiovascular Therapy 8:8, 1191-1200
CrossRef334
Martin Moser, Christoph Bode. (2010) Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. Journal of Thrombosis and Thrombolysis 30:2, 240-249
CrossRef335
Jon-David R. Schwalm, Mayraj Ahmad, Omid Salehian, John W. Eikelboom, Madhu K. Natarajan. (2010) Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. Journal of Thrombosis and Thrombolysis 30:2, 127-132
CrossRef336
Jorge F. Saucedo. (2010) Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 30:2, 200-209
CrossRef337
Nicolas Danchin, Nadia Aïssaoui. (2010) Pharmacologic Therapy for Non ST-segment Elevation Acute Coronary Syndromes: Focus on Antithrombotic Therapy. Cardiovascular Drugs and Therapy 24:4, 325-330
CrossRef338
Kumaran Kolandaivelu, Deepak L. Bhatt. (2010) Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nature Reviews Cardiology 7:8, 461-467
CrossRef339
David Vivas, Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, 217-226
CrossRef340
Dimitris Tousoulis, Ioannis Ph. Paroutoglou, Nikolaos Papageorgiou, Marietta Charakida, Christodoulos Stefanadis. (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacology & Therapeutics 127:2, 108-120
CrossRef341
Axel Åkerblom, Stefan K. James, Michail Koutouzis, Bo Lagerqvist, Ulf Stenestrand, Bodil Svennblad, Jonas Oldgren. (2010) Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:6, 470-475
CrossRef342
Scot Garg, Patrick W. Serruys. (2010) Coronary Stents. Journal of the American College of Cardiology 56:10, S1-S42
CrossRef343
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Update on the clinical development of cangrelor. Expert Review of Cardiovascular Therapy 8:8, 1069-1077
CrossRef344
Tobias Geisler, Meinrad Gawaz, Steven R. Steinhubl, Deepak L. Bhatt, Robert F. Storey, Marcus Flather. (2010) Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. Pharmacology & Therapeutics 127:2, 95-107
CrossRef345
David R. Holmes, Gregory J. Dehmer, Sanjay Kaul, Dana Leifer, Patrick T. O'Gara, C. Michael Stein. (2010) ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”. Journal of the American College of Cardiology 56:4, 321-341
CrossRef346
C. Richard Conti. (2010) Antiplatelets and Anticoagulants. Clinical Cardiology 33:7, 388-389
CrossRef347
Yee W Wong, Roshan Prakash, Derek P Chew. (2010) Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current Opinion in Cardiology 25:4, 305-311
CrossRef348
Frederic S. Resnic, Akshay Desai. (2010) Highlights from the 59th Annual Scientific Sessions of the American College of Cardiology, March 13 to 17, 2010, Atlanta, Georgia. The Journal of Thoracic and Cardiovascular Surgery 140:1, 257-259
CrossRef349
Chee Tang Chin, Matthew T. Roe, Keith A.A. Fox, Dorairaj Prabhakaran, Debra A. Marshall, Helene Petitjean, Yuliya Lokhnygina, Eileen Brown, Paul W. Armstrong, Harvey D. White, E. Magnus Ohman. (2010) Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal 160:1, 16-22.e1
CrossRef350
Richard C. Becker. (2010) Examining biology and pharmacology-based hypotheses in the PLATO trial. Journal of Thrombosis and Thrombolysis 30:1, 119-120
CrossRef351
Robert F. Storey, Kevin P. Bliden, Shankar B. Patil, Arun Karunakaran, Rosemary Ecob, Kathleen Butler, Renli Teng, Cheryl Wei, Udaya S. Tantry, Paul A. Gurbel. (2010) Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study. Journal of the American College of Cardiology 56:3, 185-193
CrossRef352
Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe, Janusz Kochman, Kurt Huber, Uwe Zeymer, Mina Madan, Daniel D. Gretler, Matthew W. McClure, Gayle E. Paynter, Vivian Thompson, Robert C. Welsh. (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal 160:1, 65-72
CrossRef353
Samir B. Damani, Eric J. Topol. (2010) The Case for Routine Genotyping in Dual-Antiplatelet Therapy. Journal of the American College of Cardiology 56:2, 109-111
CrossRef354
Young-Hoon Jeong, In-Suk Kim, Yongwhi Park, Min-Kyung Kang, Jin-Sin Koh, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. JACC: Cardiovascular Interventions 3:7, 731-741
CrossRef355
Masafumi Ueno, Sunil V Rao, Dominick J Angiolillo. (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiology 6:4, 445-453
CrossRef356
Kathleen Butler, Renli Teng. (2010) Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. British Journal of Clinical Pharmacology 70:1, 65-77
CrossRef357
Kenneth A. Jacobson, Jean-Marie Boeynaems. (2010) P2Y nucleotide receptors: promise of therapeutic applications. Drug Discovery Today 15:13-14, 570-578
CrossRef358
Miles W Behan, Derek P Chew, Philip E Aylward. (2010) The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology 25:4, 321-328
CrossRef359
Liam Smeeth, Aroon D. Hingorani. (2010) Short-term vascular risk: time to take notice?. Nature Reviews Cardiology 7:7, 409-411
CrossRef360
Guliz Erdem, Tobias Geisler, Marcus D. Flather. (2010) What Goes Into a Major Acute Coronary Syndrome Trial and What Will Future Trials Look Like?. Current Cardiology Reports 12:4, 348-355
CrossRef361
Michael Koutouzis, Lars Grip. (2010) Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Interventional Cardiology 2:3, 301-318
CrossRef362
J. Hankowitz, P. Bramlage. (2010) Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. Der Kardiologe 4:3, 239-248
CrossRef363
Ron Waksman. (2010) IIb or Not IIb. Journal of the American College of Cardiology 55:22, 2456-2458
CrossRef364
Patrick Serruys, Scot Garg, Alexandre Abizaid, John Ormiston, Stephan Windecker, Stefan Verheye, Christophe Dubois, Jim Stewart, Karl Hauptmann, Joachim Schofer, Karl Stangl, Bernhard Witzenbichler, Marcus Wiemer, Emanuele Barbato, Ton de Vries, Anne-Marie den Drijver, Hiromasa Otake, Lynn Meredith, Sara Toyloy, Peter Fitzgerald. (2010) A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention 6:2, 195-205
CrossRef365
Nihar R. Desai, Deepak L. Bhatt. (2010) The State of Periprocedural Antiplatelet Therapy After Recent Trials. JACC: Cardiovascular Interventions 3:6, 571-583
CrossRef366
Fabio Mangiacapra, Emanuele Barbato. (2010) Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine 4:3, 421-434
CrossRef367
Sotirios Tsimikas, Gregor Leibundgut. (2010) Post-Thienopyridine Platelet Response, Cardiovascular Outcomes, and Personalized Therapy. JACC: Cardiovascular Interventions 3:6, 657-659
CrossRef368
Jacob George, Alex Doney, Colin N. Palmer, Chim C. Lang. (2010) Pharmacogenetics Testing: Implications for Cardiovascular Therapeutics with Clopidogrel and Warfarin. Cardiovascular Therapeutics 28:3, 135-138
CrossRef369
Keith A.A. Fox, Tim C. Clayton, Peter Damman, Stuart J. Pocock, Robbert J. de Winter, Jan G.P. Tijssen, Bo Lagerqvist, Lars Wallentin. (2010) Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 55:22, 2435-2445
CrossRef370
Parham Eshtehardi, Stephan Windecker, Stéphane Cook, Michael Billinger, Mario Togni, Ali Garachemani, Bernhard Meier, Otto M. Hess, Peter Wenaweser. (2010) Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. American Heart Journal 159:5, 891-898.e1
CrossRef371
Renato D. Lopes, David Garcia, Richard C. Becker, Christopher B. Granger, L. Kristin Newby, John H. Alexander, E. Marc Jolicoeur, Allison Handler, Karen S. Pieper, Antonio C. Carvalho, Helio P. Guimaraes, Dalton A. F. Chamone, Antonio C. Baruzzi, Fabio S. Machado, Ari Timerman, Antonio C. Lopes. (2010) Highlights from the II international symposium of thrombosis and anticoagulation (ISTA), October 22–23, 2009, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis 29:4, 395-408
CrossRef372
Simon R. Dixon, Cindy L. Grines, William W. O'Neill. (2010) The Year in Interventional Cardiology. Journal of the American College of Cardiology 55:20, 2272-2286
CrossRef373
Helmar Bornemann, Florian Prüller, Helfried Metzler. (2010) The patient with coronary stents and antiplatelet agents: what to do and how to deal?. European Journal of Anaesthesiology 27:5, 406-410
CrossRef374
Renli Teng, Kathleen Butler. (2010) Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. European Journal of Clinical Pharmacology 66:5, 487-496
CrossRef375
Somjot S Brar, Gregg W Stone. (2010) Decision-making: stenting in acute myocardial infarction. Future Cardiology 6:3, 301-314
CrossRef376
Sergio Coccheri. (2010) Antiplatelet Drugs – Do We Need New Options?. Drugs 70:7, 887-908
CrossRef377
Jennifer S. Li, Jane W. Newburger. (2010) Antiplatelet Therapy in Pediatric Cardiovascular Patients. Pediatric Cardiology 31:4, 454-461
CrossRef378
Debbie Yee, Joanne Meyer, Gina Caliendo, Veronica Oviedo. (2010) Prasugrel, a New Platelet Inhibitor. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:3, 315-323
CrossRef379
Till F. Althoff, Matthias Fischer, Elisabeth Langer, Sabine Ziemer, Gert Baumann. (2010) Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thrombosis Research 125:5, e190-e196
CrossRef380
S. Michael Gharacholou, Renato D. Lopes, Jeffrey B. Washam, L. Kristin Newby, Stefan K. James, John H. Alexander. (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 29:4, 516-528
CrossRef381
Victor L. Serebruany. (2010) Mortality in the TRITON Trial: Update from the FDA Prasugrel Action Package. The American Journal of Cardiology 105:9, 1356-1357
CrossRef382
Akshay Desai, Frederic S. Resnic. (2010) Highlights from American Heart Association Annual Scientific Sessions 2009: Orlando, Florida, November 14–18, 2009. The Journal of Thoracic and Cardiovascular Surgery 139:4, 1090-1092
CrossRef383
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2010) The Year in Atherothrombosis. Journal of the American College of Cardiology 55:14, 1487-1498
CrossRef384
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef385
H. Darius. (2010) Update: orale Thrombozyteninhibitoren in der Kardiologie. Der Internist 51:4, 533-538
CrossRef386
V. L. Serebruany, D. Atar. (2010) The PLATO trial: do you believe in magic?. European Heart Journal 31:7, 764-767
CrossRef387
Steen Husted, Robert F. Storey, Robert A. Harrington, Håkan Emanuelsson, Christopher P. Cannon. (2010) Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel. Clinical Cardiology 33:4, 206-212
CrossRef388
Harold L. Dauerman, Deepak L. Bhatt, Daniel D. Gretler, Patricia A. French, Susan S. Smyth, Richard C. Becker. (2010) Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. American Heart Journal 159:4, 508-517.e1
CrossRef389
Graeme J Hankey, John W Eikelboom. (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. The Lancet Neurology 9:3, 273-284
CrossRef390
Scot Garg, Patrick Serruys. (2010) Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Review of Cardiovascular Therapy 8:3, 449-470
CrossRef391
Ulrike Flierl, Corinna Schöpp, Juliane Jaitner, Johann Bauersachs, Andreas Schäfer. (2010) The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats. Thrombosis Research 125:3, e93-e99
CrossRef392
Victor L. Serebruany. (2010) Clopidogrel and Heart Failure Survival. Journal of the American College of Cardiology 55:13, 1308-1309
CrossRef393
Anthony F.T. Brown, Louise Cullen, Martin Than. (2010) Future Developments in Chest Pain Diagnosis and Management. Medical Clinics of North America 94:2, 375-400
CrossRef394
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2010) Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology 35:3, 123-170
CrossRef395
David P. Faxon. (2010) Antiplatelet therapy: Cangrelor for ACS—lessons from the CHAMPION trials. Nature Reviews Cardiology 7:3, 124-125
CrossRef396
Samin K. Sharma. (2010) Oral antiplatelet therapy in PCI patients. Catheterization and Cardiovascular Interventions 75:S1, S7-S14
CrossRef397
Harald Arnesen. (2010) Thrombocardiology: an update. Expert Review of Cardiovascular Therapy 8:3, 331-333
CrossRef398
M. L. Simoons, S. Windecker. (2010) Chronic stable coronary artery disease: drugs vs. revascularization. European Heart Journal 31:5, 530-541
CrossRef399
Jolanta M Siller-Matula, Julia Krumphuber, Bernd Jilma. (2010) Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British Journal of Pharmacology 159:3, 502-517
CrossRef400
Terry K.W. Ma, Yat-Yin Lam, Victoria P. Tan, Thomas J. Kiernan, Bryan P. Yan. (2010) Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacology & Therapeutics 125:2, 249-259
CrossRef401
Luke Tapp, Eduard Shantsila, Gregory Y.H. Lip. (2010) Aspirin—A Drug Whose Time Has Gone?. The American Journal of Cardiology 105:4, 577-578
CrossRef402
Elias B. Hanna, David Luke Glancy, Jorge F. Saucedo. (2010) Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 24:1, 61-70
CrossRef403
Chetan Varma. (2010) Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. Thrombosis Research 125:2, 110-111
CrossRef404
Ali O. Abualsaud, Mark J. Eisenberg. (2010) Perioperative Management of Patients With Drug-Eluting Stents. JACC: Cardiovascular Interventions 3:2, 131-142
CrossRef405
Davide Capodanno, Kodlipet Dharmashankar, Dominick J Angiolillo. (2010) Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y 12 receptor antagonist. Expert Review of Cardiovascular Therapy 8:2, 151-158
CrossRef406
D. SIBBING, S. SCHULZ, S. BRAUN, T. MORATH, J. STEGHERR, J. MEHILLI, A. SCHÖMIG, N. VON BECKERATH, A. KASTRATI. (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis 8:2, 250-256
CrossRef407
Roberta Rossini, Giuseppe Musumeci, Alessandro Aprile, Orazio Valsecchi. (2010) Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Review of Pharmacoeconomics & Outcomes Research 10:1, 49-61
CrossRef408
Alan D. Michelson. (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 9:2, 154-169
CrossRef409
Graeme J Hankey. (2010) Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?. Current Opinion in Neurology 23:1, 65-72
CrossRef410
Carlo Patrono, Bianca Rocca. (2010) The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine 61:1, 49-61
CrossRef411
Harish Ramakrishna, Jens Fassl, Ashish Sinha, Prakash Patel, Hynek Riha, Michael Andritsos, Insung Chung, John G.T. Augoustides. (2010) The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2009. Journal of Cardiothoracic and Vascular Anesthesia 24:1, 7-17
CrossRef412
2010. General Preoperative Considerations and Preparation of the Patient for Surgery. , 129-171.
CrossRef413
L. Testa, G. G. L. Biondi Zoccai, M. Valgimigli, R. A. Latini, S. Pizzocri, S. Lanotte, M. L. Laudisa, N. Brambilla, M. R. Ward, G. A. Figtree, F. Bedogni, R. Bhindi. (2010) Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents. Advances in Hematology 2010, 1-7
CrossRef414
Inmaculada Roldán Rabadán. (2010) Nuevos antiagregantes en el síndrome coronario agudo. El futuro es hoy. Revista Española de Cardiología Suplementos 10:4, 12D-22D
CrossRef415
Ian A Menown, James A Shand. (2010) Recent advances in cardiology. Future Cardiology 6:1, 11-17
CrossRef416
Dániel Aradi, András Vorobcsuk, Zsófia Lenkey, Iván Gábor Horváth, András Komócsi. (2010) Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets 21:1, 1-10
CrossRef417
Álvaro Merino, Andrés Grau, Ignacio Segura. (2010) Novedades en el tratamiento antitrombótico en intervencionismo coronario. Revista Española de Cardiología Suplementos 10:4, 34D-41D
CrossRef418
Antonio Fernández-Ortiz, David Vivas, Juan C. García-Rubira. (2010) Tratamiento antitrombótico en diabéticos con síndrome coronario agudo. Revista Española de Cardiología Suplementos 10:4, 42D-48D
CrossRef419
Marc Bonaca, Robert P. Giugliano. (2010) Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Current Treatment Options in Cardiovascular Medicine 12:1, 84-99
CrossRef420
Victor L. Serebruany. (2010) Aspirin Dose and Ticagrelor Benefit in PLATO: Fact or Fiction?. Cardiology 117:4, 280-283
CrossRef421
Antonio Salvador Sanz. (2010) ¿Qué dicen las guías?. Revista Española de Cardiología Suplementos 10:4, 29D-33D
CrossRef422
Alfredo Bardají, José A. Barrabés, Juan Sanchis, Pedro L. Sánchez. (2010) Actualización en cardiopatía isquémica. Revista Española de Cardiología 63, 49-60
CrossRef423
Gregory W Albers. (2010) Stroke: more protection for patients with atrial fibrillation. The Lancet Neurology 9:1, 2-4
CrossRef424
Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin. (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet 375:9711, 283-293
CrossRef425
Dominick J. Angiolillo, José Luis Ferreiro. (2010) Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Revista Española de Cardiología 63:1, 60-76
CrossRef426
Loren Laine, Charles Hennekens. (2010) Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?. The American Journal of Gastroenterology 105:1, 34-41
CrossRef427
Gregg W Stone. (2010) Ticagrelor in ACS: redefining a new standard of care?. The Lancet 375:9711, 263-265
CrossRef428
Dominick J. Angiolillo, Masafumi Ueno, Shinya Goto. (2010) Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal 74:4, 597-607
CrossRef429
Samip Vasaiwala, Daniel E. Forman, Laura Mauri. (2010) Drug-Eluting Stents in the Elderly. Current Treatment Options in Cardiovascular Medicine 12:1, 76-83
CrossRef430
Bhatt, Deepak L., Lincoff, A. Michael, Gibson, C. Michael, Stone, Gregg W., McNulty, Steven, Montalescot, Gilles, Kleiman, Neal S., Goodman, Shaun G., White, Harvey D., Mahaffey, Kenneth W., Pollack, Charles V. Jr., Manoukian, Steven V., Widimsky, Petr, Chew, Derek P., Cura, Fernando, Manukov, Ivan, Tousek, Frantisek, Jafar, M. Zubair, Arneja, Jaspal, Skerjanec, Simona, Harrington, Robert A., . (2009) Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine 361:24, 2330-2341
Full Text431
(2009) Ticagrelor versus Clopidogrel in Acute Coronary Syndromes. New England Journal of Medicine 361:24, 2385-2388
Full Text432
Kastrati, Adnan, Ndrepepa, Gjin, . (2009) Cangrelor — A Champion Lost in Translation?. New England Journal of Medicine 361:24, 2382-2384
Full Text433
Harrington, Robert A., Stone, Gregg W., McNulty, Steven, White, Harvey D., Lincoff, A. Michael, Gibson, C. Michael, Pollack, Charles V. Jr., Montalescot, Gilles, Mahaffey, Kenneth W., Kleiman, Neal S., Goodman, Shaun G., Amine, Maged, Angiolillo, Dominick J., Becker, Richard C., Chew, Derek P., French, William J., Leisch, Franz, Parikh, Keyur H., Skerjanec, Simona, Bhatt, Deepak L., . (2009) Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine 361:24, 2318-2329
Full Text434
Jeroen J. Bax, Barbara Casadei, Carlo Di Mario, Robert Fagard, Gerasimos Filippatos, Keith A.A. Fox, Marco Metra, Petros Nihoyannopoulos, Joep Perk, Frank Rademakers, Raphael Rosenhek, Panos E. Vardas, Fausto J. Pinto, Roberto Ferrari. (2009) Highlights of the 2009 Scientific Sessions of the European Society of Cardiology. Journal of the American College of Cardiology 54:25, 2447-2458
CrossRef435
David Fitchett, John Eikelboom, Stephen Fremes, David Mazer, Steve Singh, Bindu Bittira, Stephanie Brister, John J. Graham, Milan Gupta, Keyvan Karkouti, Agnes Lee, Michael Love, Rod McArthur, Mark Peterson, Subodh Verma, Terrence M. Yau. (2009) Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Canadian Journal of Cardiology 25:12, 683-689
CrossRef436
Marc Cohen. (2009) Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy 23:6, 489-499
CrossRef437
Jeffrey S. Berger, Matthew T. Roe, C. Michael Gibson, Rakhi Kilaru, Cynthia L. Green, Laura Melton, James D. Blankenship, D. Christopher Metzger, Christopher B. Granger, Daniel D. Gretler, Cindy L. Grines, Kurt Huber, Uwe Zeymer, Pawel Buszman, Robert A. Harrington, Paul W. Armstrong. (2009) Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. American Heart Journal 158:6, 998-1004.e1
CrossRef438
Helge Möllmann, Holger M. Nef, Christian W. Hamm, Michael Böhm, Bodo Cremers. (2009) Highlights from Transcatheter Cardiovascular Therapeutics 2009. Clinical Research in Cardiology 98:12, 811-817
CrossRef439
Richard C Becker, James Scheiman, Harold L Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A Johnson, Frances Chan, Neena S Abraham, Eamonn M M Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. The American Journal of Gastroenterology 104:12, 2903-2917
CrossRef440
Laurent Bonello, Gilles Lemesle, Axel De Labriolle, Paul Barragan, Laurence Camoin-Jau, Franck Paganelli. (2009) Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. Expert Review of Cardiovascular Therapy 7:12, 1525-1532
CrossRef441
Richard C. Becker, James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, Frances Chan, Neena S. Abraham, Eamonn M.M. Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology 54:24, 2261-2276
CrossRef442
Jon C. George, George D. Dangas. (2009) European Society of Cardiology Congress 2009. JACC: Cardiovascular Interventions 2:11, 1160-1162
CrossRef443
Daniel R. Guerra, James E. Tcheng. (2009) Prasugrel: Clinical development and therapeutic application. Advances in Therapy 26:11, 999-1011
CrossRef444
C. Jámbor, M. Spannagl, B. Zwissler. (2009) Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Der Anaesthesist 58:10, 971-985
CrossRef445
M. Leschke. (2009) Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Der Anaesthesist 58:10, 969-970
CrossRef446
Schömig, Albert, . (2009) Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?. New England Journal of Medicine 361:11, 1108-1111
Full Text447
Toshikazu JINNAI, Hisanori HORIUCHI. (2009) Variability of the antiplatelet effect of clopidogrel in Japanese. Japanese Journal of Thrombosis and Hemostasis 20:6, 589-593
CrossRef448
Stephen H Little, David R Massel, Stephen H Little. 2003. Antiplatelet and anticoagulation for patients with prosthetic heart valves. .
CrossRef
- Letters
